NZ626580B2 - Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof - Google Patents
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof Download PDFInfo
- Publication number
- NZ626580B2 NZ626580B2 NZ626580A NZ62658012A NZ626580B2 NZ 626580 B2 NZ626580 B2 NZ 626580B2 NZ 626580 A NZ626580 A NZ 626580A NZ 62658012 A NZ62658012 A NZ 62658012A NZ 626580 B2 NZ626580 B2 NZ 626580B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- vactriib
- polypeptide
- seq
- set forth
- amino acid
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 261
- 102000018918 Activin Receptors Human genes 0.000 title description 4
- 108010052946 Activin Receptors Proteins 0.000 title description 4
- 238000002512 chemotherapy Methods 0.000 title description 4
- 150000001413 amino acids Chemical class 0.000 claims abstract description 104
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 74
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 74
- 102100019916 MSTN Human genes 0.000 claims abstract description 73
- 108010056852 Myostatin Proteins 0.000 claims abstract description 69
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 108010023082 activin A Proteins 0.000 claims abstract description 62
- 108010059616 Activins Proteins 0.000 claims abstract description 55
- 239000000488 activin Substances 0.000 claims abstract description 54
- 102100008240 INHBE Human genes 0.000 claims abstract description 52
- 238000006467 substitution reaction Methods 0.000 claims abstract description 48
- 230000027455 binding Effects 0.000 claims abstract description 42
- 201000011510 cancer Diseases 0.000 claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 32
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 20
- 102100003272 GDF11 Human genes 0.000 claims abstract description 13
- 101700065866 GDF11 Proteins 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 18
- 206010028980 Neoplasm Diseases 0.000 claims description 89
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 229910052700 potassium Inorganic materials 0.000 claims description 38
- 230000002611 ovarian Effects 0.000 claims description 32
- 229910052721 tungsten Inorganic materials 0.000 claims description 31
- 229910052727 yttrium Inorganic materials 0.000 claims description 31
- 229910052740 iodine Inorganic materials 0.000 claims description 23
- 206010033128 Ovarian cancer Diseases 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- -1 n A Proteins 0.000 claims description 13
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 claims description 11
- 229960003901 dacarbazine Drugs 0.000 claims description 11
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 229960002949 Fluorouracil Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 210000004027 cells Anatomy 0.000 description 81
- 235000001014 amino acid Nutrition 0.000 description 79
- 235000018102 proteins Nutrition 0.000 description 64
- 230000000694 effects Effects 0.000 description 60
- 101710024843 ACVR2B Proteins 0.000 description 51
- 239000003981 vehicle Substances 0.000 description 47
- 230000014509 gene expression Effects 0.000 description 35
- 239000002773 nucleotide Substances 0.000 description 34
- 125000003729 nucleotide group Chemical group 0.000 description 34
- 108090001123 antibodies Proteins 0.000 description 33
- 102000004965 antibodies Human genes 0.000 description 33
- 241000282414 Homo sapiens Species 0.000 description 30
- 210000003205 Muscles Anatomy 0.000 description 30
- 102200083508 DRAM1 E28Q Human genes 0.000 description 27
- 102000005962 receptors Human genes 0.000 description 26
- 108020003175 receptors Proteins 0.000 description 26
- 201000010099 disease Diseases 0.000 description 24
- 230000001965 increased Effects 0.000 description 24
- 230000037396 body weight Effects 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 201000000585 muscular atrophy Diseases 0.000 description 20
- 230000002776 aggregation Effects 0.000 description 19
- 238000004220 aggregation Methods 0.000 description 19
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- 206010028289 Muscle atrophy Diseases 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 17
- 229920000023 polynucleotide Polymers 0.000 description 17
- 239000002157 polynucleotide Substances 0.000 description 17
- 102220449826 KIR3DL3 R64A Human genes 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 230000012010 growth Effects 0.000 description 14
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 13
- 238000002513 implantation Methods 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 230000002018 overexpression Effects 0.000 description 12
- 230000002829 reduced Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000004083 survival Effects 0.000 description 12
- 210000000988 Bone and Bones Anatomy 0.000 description 11
- 206010006895 Cachexia Diseases 0.000 description 11
- 241000699660 Mus musculus Species 0.000 description 11
- 230000001225 therapeutic Effects 0.000 description 11
- 210000001519 tissues Anatomy 0.000 description 11
- 102000003952 Caspase 3 Human genes 0.000 description 10
- 108090000397 Caspase 3 Proteins 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 210000001672 Ovary Anatomy 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 102200048627 CCL3 R40A Human genes 0.000 description 8
- 210000003141 Lower Extremity Anatomy 0.000 description 8
- 206010025650 Malignant melanoma Diseases 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 230000000903 blocking Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000002381 testicular Effects 0.000 description 8
- 102100015249 VEGFA Human genes 0.000 description 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 230000003042 antagnostic Effects 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 239000002609 media Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000006011 modification reaction Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 6
- 206010061379 Testicular neoplasm Diseases 0.000 description 6
- 210000001550 Testis Anatomy 0.000 description 6
- 239000003098 androgen Substances 0.000 description 6
- 239000003636 conditioned culture media Substances 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000003627 Muscular Dystrophy Diseases 0.000 description 5
- 210000002966 Serum Anatomy 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000000295 complement Effects 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 201000006938 muscular dystrophy Diseases 0.000 description 5
- 230000003472 neutralizing Effects 0.000 description 5
- 210000000056 organs Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000002459 sustained Effects 0.000 description 5
- 201000003120 testicular cancer Diseases 0.000 description 5
- 229910052718 tin Inorganic materials 0.000 description 5
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 5
- 229920002676 Complementary DNA Polymers 0.000 description 4
- 206010012601 Diabetes mellitus Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 229940014259 Gelatin Drugs 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 108050006583 Growth/differentiation factor 8 Proteins 0.000 description 4
- 102220413779 HLA-DPB1 E10A Human genes 0.000 description 4
- 206010022114 Injury Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229920001850 Nucleic acid sequence Polymers 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010057644 Testis cancer Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000004059 degradation Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000002710 gonadal Effects 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 102220204833 rs1057522953 Human genes 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 3
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 3
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 3
- 102000005606 Activins Human genes 0.000 description 3
- 108010071919 Bispecific Antibodies Proteins 0.000 description 3
- 102100004728 CDH1 Human genes 0.000 description 3
- 101700016900 CDH1 Proteins 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 230000036499 Half live Effects 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108020004999 Messenger RNA Proteins 0.000 description 3
- 208000008466 Metabolic Disease Diseases 0.000 description 3
- 210000004165 Myocardium Anatomy 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 206010038435 Renal failure Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- 229940035295 Ting Drugs 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 229930013930 alkaloids Natural products 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 238000006664 bond formation reaction Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000000973 chemotherapeutic Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000002055 immunohistochemical Effects 0.000 description 3
- 230000001976 improved Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229920002106 messenger RNA Polymers 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000036961 partial Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 101710040918 shg Proteins 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000003442 weekly Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 Aminoglutethimide Drugs 0.000 description 2
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 description 2
- 108010055216 Anti-Idiotypic Antibodies Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 229960001230 Asparagine Drugs 0.000 description 2
- 206010003549 Asthenia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 229940077737 Brain-Derived Neurotrophic Factor Drugs 0.000 description 2
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 description 2
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- 102000003712 Complement Factor B Human genes 0.000 description 2
- 108090000056 Complement Factor B Proteins 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L Copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 102000036640 Cullin Ring E3 Ligases Human genes 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 102200153424 GJB1 R22G Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010018987 Haemorrhage Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 210000004379 Membranes Anatomy 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- HDZGCSFEDULWCS-UHFFFAOYSA-N Monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 108010008267 Nerve Growth Factors Proteins 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000004361 Obstructive Lung Disease Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 2
- 108010033725 Recombinant Proteins Proteins 0.000 description 2
- 102000007312 Recombinant Proteins Human genes 0.000 description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007374 Smad Proteins Human genes 0.000 description 2
- 108010007945 Smad Proteins Proteins 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 2
- 229960003048 Vinblastine Drugs 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 241000863480 Vinca Species 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- 208000010399 Wasting Syndrome Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000001472 cytotoxic Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000005486 microgravity Effects 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 238000002534 molecular mass spectrometry Methods 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- 230000000921 morphogenic Effects 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 2
- 108091008117 polyclonal antibodies Proteins 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 230000001737 promoting Effects 0.000 description 2
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 231100000803 sterility Toxicity 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002103 transcriptional Effects 0.000 description 2
- 230000001052 transient Effects 0.000 description 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 2
- 210000004881 tumor cells Anatomy 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2S)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4S,4aS,5aS,6S,12aR)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N 17-Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-N-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 108060005293 AGA Proteins 0.000 description 1
- 229940030486 ANDROGENS Drugs 0.000 description 1
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 description 1
- 102100004323 ASPG Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000432074 Adeno-associated virus Species 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
- 102000009075 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- 229960002170 Azathioprine Drugs 0.000 description 1
- 206010003885 Azotaemia Diseases 0.000 description 1
- 101700078037 BIND Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O Bleomycin Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000003432 Bone Disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 1
- 101700010918 CPP1 Proteins 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000003295 Carpal Tunnel Syndrome Diseases 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 210000003855 Cell Nucleus Anatomy 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960003260 Chlorhexidine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 230000035700 Clearance Rate Effects 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229940099500 Cystamine Drugs 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 102100005838 DHFR Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 description 1
- 206010061835 Diabetic nephropathy Diseases 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N Diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N Dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 210000002351 Embryonic Muscle Cell Anatomy 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- LLQPHQFNMLZJMP-UHFFFAOYSA-N Fentrazamide Chemical compound N1=NN(C=2C(=CC=CC=2)Cl)C(=O)N1C(=O)N(CC)C1CCCCC1 LLQPHQFNMLZJMP-UHFFFAOYSA-N 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960001751 Fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N Fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 210000002758 Humerus Anatomy 0.000 description 1
- 210000004408 Hybridomas Anatomy 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 102100015972 IL2 Human genes 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- 210000003000 Inclusion Bodies Anatomy 0.000 description 1
- 206010022489 Insulin resistance Diseases 0.000 description 1
- 102000004372 Insulin-Like Growth Factor Binding Protein 2 Human genes 0.000 description 1
- 108090000964 Insulin-Like Growth Factor Binding Protein 2 Proteins 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 210000002414 Leg Anatomy 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 229960004296 Megestrol Acetate Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 210000004413 Myocytes, Cardiac Anatomy 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N N-tert-butyl-N-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 229920002957 Naked DNA Polymers 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010058823 Ovarian mass Diseases 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 102100018954 PECAM1 Human genes 0.000 description 1
- 101710027269 PECAM1 Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229960002340 Pentostatin Drugs 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 229940088087 Plant Drugs 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229940068977 Polysorbate 20 Drugs 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 229940068965 Polysorbates Drugs 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920001785 Response element Polymers 0.000 description 1
- 101710023380 S100A8 Proteins 0.000 description 1
- 102100017875 S100A8 Human genes 0.000 description 1
- 208000001076 Sarcopenia Diseases 0.000 description 1
- 210000002863 Seminiferous Tubules Anatomy 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N Sinapinic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 210000002356 Skeleton Anatomy 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 210000002921 Spermatogonia Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N Staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- 229940063683 Taxotere Drugs 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 229960001712 Testosterone Propionate Drugs 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 210000002303 Tibia Anatomy 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 240000008529 Triticum aestivum Species 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 208000009852 Uremia Diseases 0.000 description 1
- 241001459538 Ute Species 0.000 description 1
- 210000003501 Vero Cells Anatomy 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 230000001780 adrenocortical Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000009167 androgen deprivation therapy Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000002317 cardiac myocyte Anatomy 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000001925 catabolic Effects 0.000 description 1
- 101700052859 cdf-1 Proteins 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003196 chaotropic Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 101700032836 cinC Proteins 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960003280 cupric chloride Drugs 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 230000003412 degenerative Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000011118 depth filtration Methods 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical class C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 102000018146 globin family Human genes 0.000 description 1
- 108060003196 globin family Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- XKUUMWKWUZRRPD-UHFFFAOYSA-N heptan-2-amine;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.CCCCCC(C)[NH3+].CCCCCC(C)[NH3+] XKUUMWKWUZRRPD-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 230000003345 hyperglycaemic Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 101710009906 lbp-2 Proteins 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 201000009342 limb-girdle muscular dystrophy Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000010603 microCT Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000035365 modified proteins Human genes 0.000 description 1
- 108091005569 modified proteins Proteins 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 239000003956 nonsteroidal anti androgen Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 201000003733 ovarian melanoma Diseases 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920003250 poly(2-hydroxyethyl methacrylate) Polymers 0.000 description 1
- 108010087782 poly(glycyl-alanyl) Proteins 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001711 protein immunostaining Methods 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 239000004017 serum-free culture media Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 239000012443 tonicity enhancing agent Substances 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000001875 tumorinhibitory Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000021307 wheat Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N β-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
Abstract
Disclosed is a pharmaceutical composition comprising (i) an isolated protein comprising a variant activin IIB receptor polypeptide (vActRIIB), wherein vActRIIB comprises a polypeptide sequence having at least 95% identity to the amino acid sequence set forth at amino acids 25 through 134 of the sequence set forth in SEQ ID NO:18, wherein the polypeptide comprises an amino acid substitution at position 28, and wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11, and (ii) a chemotherapeutic agent. Also disclosed is the use of such compositions in the manufacture of a medicament for treating cancer. ence set forth in SEQ ID NO:18, wherein the polypeptide comprises an amino acid substitution at position 28, and wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11, and (ii) a chemotherapeutic agent. Also disclosed is the use of such compositions in the manufacture of a medicament for treating cancer.
Description
VARIANT ACTIVIN RECEPTOR POLYPEPTIDES, ALONE OR IN COMBINATION WITH
CHEMOTHERAPY, AND USES THEREOF
CROSS-REFERENCE TO RELATED APPLICATIONS
[000 1] This application claims the right of ty based on US. Serial No.
13/329,897, filed December 19, 2011, the entire disclosure of which is herein incorporated by
reference, in its entirety, for all purposes.
This application is d to US. Serial No. 13/080,515, filed April 5, 2011,
now pending, which is a divisional of US. Serial No. 12/074,877, filed March 5, 2008, now
d as U. S. Patent No. 7,947,646 which claims the benefit of United States provisional
application serial number 61/065,474, filed February 11, 2008, and United States provisional
application serial number 60/905,459, filed March 6, 2007, the disclosures of which are relied
upon and incorporated by reference herein.
REFERENCE TO THE SEQUENCE LISTING
The present application is being filed along with a Sequence Listing in
electronic format. The Sequence Listing is provided as a file entitled AUS-
CIP_SeqList.txt which is 265,085 bytes in size, and was created December 19, 2011. The
information in the electronic format of the Sequence Listing is orated herein by reference
in its entirety
FIELD OF THE INVENTION
The technical field of this invention relates to transforming growth factor-B
(TGF-B) family s and soluble TGF-B receptors, as well as methods of modulating the
activities of TGF—B family members for the treatment of various disorders.
OUND OF THE INVENTION
The orming growth factor B (TGF-B) family of proteins includes the
orming growth factors-B (TGF-B), ns, bone morphogenic ns (BMP), nerve
growth factors (NGFs), brain-derived neurotrophic factor (BDNF), and growth/differentiation
factors (GDFs). These family members are involved in the tion of a wide range of
biological processes including cell proliferation, differentiation, and other functions.
Growth/differentiation factor 8 (GDF-8), also referred to as myostatin, is a
TGF-B family member expressed for the most part in the cells of developing and adult skeletal
muscle tissue. Myostatin appears to play an essential role in negatively controlling skeletal
muscle growth (McPherron et al., Nature (London) 387, 83-90 ). Antagonizing
myostatin has been shown to increase lean muscle mass in animals (McFerron et al., supra,
s et al., Science 296:1486 (2002)).
Another member of the TGF-B family of proteins is a related growth/
differentiation factor, GDF-11. GDF-11 has imately 90% identity of the amino acid
sequence of myostatin. GDF-11 has a role in the axial patterning in developing animals (Oh et
al, Genes Dev 11:1812-26 (1997)), and also appears to play a role in skeletal muscle
development and .
Activins A, B and AB are the homodimers and heterdimer respectively of two
polypeptide chains, BA and BB (Vale et al. Nature 321, 776-779 (1986), Ling et al., Nature 321,
779-782 ). Activins were originally discovered as gonadal peptides ed in the
tion of follicle stimulating hormone synthesis, and are now believed to be involved in the
regulation of a number of biological ties. Activin A is a predominant form of activin.
Activin, myostatin, GDF-11 and other members of the TGF- B superfamily bind
and signal through a combination of activin type II and activin type IIB receptors, both of
which are transmembrane serine/threonine s son et al., J. Biol. Chem. 279, 28036-
28044 (2004)). linking studies have determined that myostatin is capable of binding the
activin type 11 receptors ActRIIA and ActRIIB in vitro (Lee et al., PNAS USA 98:9306-11
(2001)). There is also evidence that GDF-11 binds to both ActRIIA and ActRIIB (Oh et al.,
Genes Dev 16:2749-54 ).
[00 1 0] TGF-B protein expression is known to be associated with a variety of diseases
and disorders. ore, therapeutic molecules capable of antagonizing several TGF-B
proteins simultaneously may be particularly effective for these diseases and disorders.
[00 1 1] In addition, the production of protein therapeutics can be complicated by
problems ing during the expression and purification of the protein. One problem is the
aggregation of proteins during sion or purif1cation. The accumulation of high levels of
protein during cell culture conditions may lead to aggregation. Purif1cation processes may
expose the protein to onal factors promoting further aggregation (Cromwell, M.E.M. et
al., The AAPS Journal 8:E572-E579, 2006). Attempts can be made to te the factors that
cause aggregation, however, a need exists for proteins designed to have a decreased tendency to
form aggregates. The present invention fillfillS the need for therapeutic molecules that bind to
multiple ligands, and have reduced aggregation and thus improved manufacturability, in order
to efficiently produce proteins useful for treating TGF-B related disease states.
SUMMARY OF THE INVENTION
[00 1 2] The present ion provides an isolated protein sing a variant human
activin receptor IIB (designated vActRIIB or sActRIIB) polypeptide. As used herein the term
vActRIIB polypeptide refers to both human vActRIIB polypeptides and human vActRIIBS
polypeptides. In one embodiment, the protein comprises a polypeptide having an amino acid
sequence of SEQ ID NOS: 2 or 18 in which amino acids at either position E28 or R40, or both
position E28 and R40 are substituted with another non-native amino acid, and wherein the
polypeptide is capable of binding myostatin, activin A, or GDF-l I. In one embodiment the
protein comprises a polypeptide having an amino acid sequence of SEQ ID NOS: 2 or 18 in
which the amino acids at positions E28 or R40, or both E28 and R40 are substituted with a non-
native amino acid, and wherein the signal peptide is removed, and wherein the polypeptide is
capable of binding myostatin, activin A, or GDF-l I. In one ment the protein comprises
a polypeptide having an amino acid ce of SEQ ID NOS: 2 or 18 in which amino acids at
positions E28 or R40, or both E28 and R40 are substituted with another amino acid, wherein
the signal sequence is removed, and N-terminal of the mature polypeptide is truncated, and
wherein the polypeptide is capable of binding myostatin, activin A, or GDF-l I. In one
embodiment the inal mature truncated vActRIIB polypeptide lacks the N-terminal four
amino acids or the N-terminal six amino acids of the mature sequence, wherein the polypeptide
is capable of binding myostatin, activin A, or GDF-l I. In one embodiment, the substitution at
position E28 is selected from the group consisting of W, Y and A. In a further embodiment,
the substitution at position E28 is selected from the group of amino acids consisting of A, F, Q,
V, I, L, M, K, H, W and Y. In a r embodiment, the substitution at position R40 is
selected from the group of amino acids ting of G, Q, M, H, K and N. In a further
embodiment the substitution at position E28 is selected from the group of amino acids
consisting of A, F, Q, V, I, L, M, K, H, W and Y and the substitution at position R40 is selected
from the group of amino acids consisting of A, G, Q, M, H, K and N. In a further embodiment
the ptide further comprises a heterologous protein. In one embodiment, the logous
n is an Fc domain. In a further ment, the Fc domain is a human IgG Fc domain.
[00 1 3] In one embodiment, the protein ses polypeptides having an amino acid
sequence set forth in SEQ ID NOS: 4, 6, 8, 10, l2, l4, 16, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38,
40, 42, 44, 46, 52, 54, 56, 60, 62, 64, 66, 70, 72, 87, 88, 91, 93, 95, and 97.
[00 1 4] In r ment, the protein comprises a polypeptide encoded by the
polynucleotide having the sequence set forth in SEQ ID NOS: 3, 5, 7, 9, ll, 13, 15, 19, 21, 23,
, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 51, 53, 55, 59, 61, 63, 65, 67, 69, 71, 92, 94, 96 or its
complement.
[00 1 5] In r aspect the present invention es an isolated nucleic acid
molecule comprising a polynucleotide encoding a vActRIIB polypeptide. In one ment,
the nucleic acid molecule comprises a polynucleotide having the c acid sequence set forth
in SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 51,
53, 55, 59, 61, 63, 65, 69, 71, 92, 94, 96 or its complement.
[00 1 6] In r embodiment, the nucleic acid le comprises a polynucleotide
encoding a polypeptide consisting of the amino acid sequence set forth in the group consisting
of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 52,
54, 56, 60, 62, 64, 66, 68, 70, 72, 87, 88, 91, 93, 95, and 97. In a further embodiment, the
nucleic acid molecule filrther comprises a transcriptional or translational regulatory sequence.
In r aspect a recombinant vector sing the vActRIIB nucleic acid molecule is
ed. In r aspect, host cells comprising the recombinant vectors are provided, and
methods of producing the vActRIIB polypeptides are provided.
[00 1 7] The present invention fiarther provides a composition containing at least one
vActRIIB polypeptide or protein of the present invention. In one embodiment, the composition
is a pharmaceutical composition containing the vActRIIB polypeptide or protein in admixture
with a pharmaceutically acceptable carrier.
[00 1 8] In another aspect, the present invention provides a method of treating or
preventing a muscle wasting disease in a t suffering from such a disorder by
administering a therapeutic composition containing a vActRIIB polypeptide or n to the
subject. The muscle wasting disease includes or results from, but is not limited to, the
following conditions: cancer cachexia, muscular dystrophy, amyotrophic lateral sclerosis,
congestive obstructive pulmonary disease, chronic heart failure, chemical ia, cachexia
from HIV/AIDS, renal failure, uremia, rheumatoid arthritis, age-related sarcopenia, age-related
frailty, organ atrophy, carpal tunnel syndrome, androgen deprivation, and muscle-wasting due
to inactivity from prolonged bed rest, spinal chord injury, stroke, bone fracture, and aging. The
muscle wasting may also result from weightlessness due to space flight, insulin resistance,
muscle wasting due to burns, androgen deprivation, and other disorders. In r aspect, the
present invention es a method of treating a e correlated to sion of activin A.
In one embodiment, the disease is . In another aspect, the present invention provides a
method of treating a metabolic disorder comprising administering a therapeutic composition to
a subject in need of such treatment, wherein the metabolic disorder is selected from bone loss,
2012/070571
diabetes, obesity, impaired e tolerance, hyperglycemia, androgen deprivation, and
metabolic syndrome. In another aspect, the present invention provides a method of gene
therapy comprising administering a vector encoding a vActRIIB polypeptide or protein of the
present invention to a subject in need thereof, wherein the vector is capable of expressing the
vActRIIB polypeptide or protein in the subject.
[00 1 9] In r ment, a pharmaceutical composition is provided comprising i)
a variant activin IIB receptor polypeptide (vActRIIB) wherein said polypeptide comprises the
polypeptide sequence of SEQ ID NO: 18 except for a single amino acid substitution at position
28, wherein the ptide is e of binding tin, activin A, or GDF-l l, and
ii) a chemotherapeutic agent. The variant activin IIB receptor of the pharmaceutical
composition can have a substitution at position 28 of the vActRIIB polypeptide that is selected
from the group consisting of A, F, Q, V, I, L, M, K, H, W and Y for E. In another embodiment
the substitution at on 28 of the vActRIIB polypeptide is selected from the group of amino
acids ting of A, W and Y for E or the substitution at position 28 of the vActRIIB
polypeptide is W. In yet other embodiments, the vActRIIB polypeptide lacks the inal
signal sequence. In yet other embodiments, the pharmaceutical also comprises a
pharmaceutically acceptable carrier, a chemotherapeutic and the activin IIB receptor
polypeptide t.
In another aspect, the chemotherapeutic agent of the pharmaceutical
composition is a side analogue. In other embodiments, the chemotherapeutic agent can
be 5-fluorouracil or dacarbazine.
[002 1] In another embodiment, a method of inhibiting myostatin activity in a subject in
need of such treatment is provided comprising administering to the subject a therapeutically
effective amount of a pharmaceutical composition comprising i) a variant activin IIB receptor
ptide (vActRIIB) n said ptide comprises the polypeptide sequence of SEQ
ID NO: 18 except for a single amino acid substitution at position 28, wherein the polypeptide is
capable of binding myostatin, activin A, or GDF-l l, and ii) a chemotherapeutic agent. The
variant activin IIB receptor of the pharmaceutical composition can have a substitution at
position 28 of the vActRIIB polypeptide that is selected from the group consisting of A, E, Q,
V, I, L, M, K, H, W and Y for E. In other embodiment the substitution at position 28 of the
vActRIIB polypeptide is selected from the group of amino acids consisting of A, W and Y for
E or the substitution at position 28 of the vActRIIB polypeptide is W. In yet other
embodiments, the vActRIIB ptide lacks the N—terminal signal sequence.
In another aspect, a method of treating a disease in which activin is over-
expressed in a subject in need of such treatment is provided comprising administering to a
subject a eutically effective amount of the composition comprising i) a variant activin IIB
receptor polypeptide IIB) wherein said ptide ses the polypeptide ce
of SEQ ID NO: 18 except for a single amino acid substitution at position 28, n the
polypeptide is capable of binding myostatin, activin A, or GDF-l l, and ii) a chemotherapeutic
agent. The t activin IIB receptor of the pharmaceutical composition can have a
substitution at on 28 of the vActRIIB polypeptide that is selected from the group
consisting of A, F, Q, V, I, L, M, K, H, W and Y for E. In other embodiment the substitution at
position 28 of the vActRIIB polypeptide is selected from the group of amino acids consisting of
A, W and Y for E or the substitution at position 28 of the vActRIIB polypeptide is W. In yet
other ments, the vActRIIB polypeptide lacks the N—terminal signal sequence.
In an aspect of the invention, the above method can be used to treat cancers.
The cancers can be testicular cancer, ovarian cancer or melanoma.
In another embodiment, a method of reducing the size of a tumor mass in a
subject in need of such treatment is provided comprising administering an ive amount of a
pharmaceutical ition comprising i) a variant activin IIB receptor polypeptide
(vActRIIB) wherein said polypeptide comprises the polypeptide sequence of SEQ ID NO: 18
except for a single amino acid substitution at position 28, wherein the polypeptide is capable of
binding myostatin, activin A, or GDF-l l, and ii) a chemotherapeutic agent. The variant
activin IIB or of the ceutical composition can have a substitution at position 28 of
the IB polypeptide that is ed from the group consisting of A, E, Q, V, I, L, M, K,
H, W and Y for E. In other embodiment the substitution at position 28 of the vActRIIB
polypeptide is selected from the group of amino acids consisting of A, W and Y for E or the
substitution at position 28 of the vActRIIB polypeptide is W. In yet other embodiments, the
vActRIIB polypeptide lacks the N—terminal signal sequence. The tumor mass can result from
testicular or ovarian cancer or a melanoma.
In yet another embodiment, a method of treating melanoma, in a subject in need
of such treatment is provided comprising administering to said subject a therapeutically
effective amount of a pharmaceutical composition comprising a variant activin IIB receptor
polypeptide IIB) wherein said polypeptide comprises the polypeptide sequence of SEQ
ID NO: 18 except for a single amino acid substitution at position 28, wherein the polypeptide is
capable of binding myostatin, activin A, or GDF-l l.
In another embodiment, a method of treating a condition having overexpression
of angiogenesis factors, in a subject in need of such ent is provided comprising
administering to said subject a therapeutically effective amount of a pharmaceutical
composition comprising a t activin IIB receptor polypeptide (vActRIIB) wherein said
polypeptide comprises the polypeptide sequence of SEQ ID NO: 18 except for a single amino
acid substitution at position 28, wherein the polypeptide is capable of binding myostatin,
n A, or GDF-l l. The condition can be cancer and the cancer can be ovarian cancer.
VEGF-A or Ang-l can be overexpressed.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. Figure 1 shows the amino acid ce of wild-type e
ActRIIB-human IgGch (SEQ ID NO: 98). The signal peptide sequence is in bold, followed
by the mature ActRIIB extracellular , and the human IgG1 Fc in italics, ing a
partial hinge region. Amino acids E28 and R40 are ined. The linker sequence GGGGS
(SEQ ID NO: 75) is in italics and underlined.
Figure 2. Figure 2 shows the amino acid sequence of e ActRIIBS-human
IgGch (SEQ ID NO: 99). The signal peptide sequence is in bold, followed by the mature
ActRIIBS soluble domain, and the human IgG1 Fc, including a partial hinge region, is in
italics. E28 and R40 are underlined. The linker sequence ) (SEQ ID NO: 75) is in
italics and underlined.
Figure 3. Figure 3 shows the effect of soluble vActRIIB-Fc E28W treatment on
testicular (Figure 3A) and ovarian (Figure 3B) mass in inhibin-(x knockout mice.
Figures 4A-4B. Figure 4 shows the effect of soluble vActRIIB-Fc E28W
treatment on survival rates in male (Figure 4A) and female (Figure 4B) inhibin-(x knockout
mice.
[003 1] Figure 5. Figure 5 shows the effect of soluble vActRIIB-Fc E28W treatment on
body weight in colon 26 tumor-bearing mice.
Figure 6. Figure 6 shows the effect of soluble vActRIIB-Fc E28W treatment on
the survival of colon 26 tumor bearing mice.
Figures 7A-7D show activin levels in mice (Figure 7A) and the effect of
IB (E28W) on ovarian cancer (OC) (Figures 7A-7D) in KO mice. Figure 7A shows
levels of activin in normal and ovarian cancer. ***P<0.001, Student t-test; n=20. Figure 7B
shows the effect of sActRIIB on activin levels. Values are mean i SEM. ***: P<0.001 vs. WT
control. n=6-12. Figure 7C shows s in ovarian mass with sActRIIB. Values are mean i
SEM. ***: P<0.001 vs. WT control. n=6-10. Figure 7D shows ovarian tumors in treated and
non-treated mice. Scale bar = 10 mm
Figures 8A-8B show ActiVin A blockade abolishes overexpression ofVEGF
levels in ovarian tumors (Figure 8A) and activation of e-3 in testicular tumors following
treatment with sActRIIB (E28W) e 8B). Figure 8A - Values are mean SEM. *: P<0.05;
Student t-test. n=10. Figure 8B- ** P<0.01, Student t-test.
Figures 9A-9B show the effect of activin nist IB (E28W) and
cytotoxic chemotherapeutic agents on tumor growth. Figure 9A shows the effect of sActRIIB
and S-Fu on TOV-21G tumor growth inhibition in nude mice. s in tumor volumes were
recorded longitudinally. ***: P<0.001 vs. PBS; #: P<0.05 vs. 5-Fu; 1: P<0.01 vs. sActRIIB;
Repeated measures ANOVA; n=12. Figure 9B shows the effect of sActRIIB and dacarbazine
on the growth of G361 human melanoma xenografts in nude mice. Results of tumor volume
(mm3) are expressed as the mean :: SEM. *: P<0.05 vs. PBS group. Statistics based on repeated
measures ANOVA. n=8.
DETAILED DESCRIPTION
[003 6] ns comprising variant human n IIB receptor (vActRIIB; also referred
to as sActRIIB) polypeptides are disclosed. These proteins and polypeptides are terized
by their ability to bind to at least one of three TGF-B proteins, myostatin (GDF-8), activin A,
and GDF-11, and to inhibit the activities of these proteins. These proteins and polypeptides
also exhibit a reduced tendency to aggregate compared to polypeptides not containing the
modifications disclosed herein. The modifications consist of amino acid substitutions at
positions 28, 40, or both 28 and 40 with reference to wild type ActRIIB of accession number
NP_OOlO97 (SEQ ID NO: 47), and the extracellular domain of ActRIIB (SEQ ID NO: 18) or
ActRIIBS (SEQ ID NO: 2).
[003 7] As used herein the term “TGF-B family members” or “TGF-B proteins” refers to
the structurally related growth factors of the transforming growth factor family including
activins, and growth and differential factor (GDF) proteins (Kingsley et al. Genes DeV. 8: 133-
146 (1994), McPherron et al. Growth s and cytokines in health and disease, Vol. 1B, D.
LeRoith and C.Bondy. ed., JAI Press Inc., Greenwich, Conn, USA: pp 357-393).
[003 8] GDF-8, also ed to as myostatin, is a ve regulator of skeletal muscle
tissue (McPherron et al. PNAS USA 94: 12457-12461 (1997)). Myostatin is synthesized as an
inactive protein complex approximately 375 amino acids in length, having GenBank Accession
No: AAB86694 (SEQ ID NO: 49) for human. The precursor protein is activated by proteolytic
cleavage at a tetrabasic sing site to produce an N—terminal inactive prodomain and an
approximately 109 amino acid C-terminal protein which dimerizes to form a homodimer of
about 25 kDa. This homodimer is the mature, biologically active protein (Zimmers et al.,
Science 296, 1486 (2002)).
[003 9] As used herein, the term “prodomain” or “propeptide” refers to the inactive N-
terminal protein which is cleaved off to release the active C-terminal protein. As used herein
the term atin” or “mature myostatin” refers to the mature, biologically active C-terminal
polypeptide, in monomer, dimer or other form, as well as biologically active fragments or
related polypeptides including allelic variants, splice variants, and fusion peptides and
polypeptides. The mature myostatin has been reported to have 100% ce identity among
many s including human, mouse, chicken, porcine, , and rat (Lee et al., PNAS 98,
9306 (2001)).
As used herein GDF-ll refers to the BMP (bone morphogenic protein) having
Swissprot accession number 095390 (SEQ ID NO: 50), as well as variants and species
homologs of that protein. GDF-ll has approximately 90% ty to myostatin at the amino
acid level. GDF-ll is involved in the tion of anterior/posterior patterning of the axial
skeleton (McPherron et al, Nature Genet. 22 (93): 260-264 (1999); Gamer et al, Dev. Biol. 208
(1), 222-232 (1999)) but postnatal functions are unknown.
[004 1] Activin A is the homodimer of the ptide chains BA. As used herein the
term “activin A” refers to the activin protein having GenBank Accession No: NM_002192
(SEQ ID NO: 48), as well as variants and species gs of that protein.
ACTIVIN RECEPTORS
As used herein, the term activin type II B receptors (ActRIIB) refers to human
n receptors having accession number NP_001097 (SEQ ID NO: 47). The term soluble
ActRIIB encompasses the extracellular domain of ActRIIB (SEQ ID NO: 18), B5 (SEQ
ID NO: 2) and these sequences wherein the arginine at position 64 is substituted with alanine,
as well as.
VARIANT SOLUBLE ActRIIB PTIDES
[0 043] The t invention provides isolated ns comprising human variant
soluble ActIIB receptor polypeptides (referred to herein as vActRIIB polypeptides, or variant
polypeptides or IB). As used herein the term “VActRIIB protein” refers to a protein
comprising a vActRIIB polypeptide. As used herein the term “isolated” refers to a protein or
polypeptide molecule purified to some degree from endogenous material. These polypeptides
and proteins are characterized as having the y to bind and inhibit the activity of any one of
activin A, myostatin, or GDF-l 1. In some embodiments, the binding affinity of the variant
polypeptides for activin A, myostatin, or GDF-ll is improved ed to wild-type
polypeptides.
In one embodiment, the VActRIIB polypeptide has the amino acid sequence of
SEQ ID NOS: 2 or 18 in which amino acids at either position E28 or R40, or both position E28
and R40 are substituted with another non-native amino acid, and wherein the ptide is
capable of binding myostatin, activin A, or GDF-l 1. In another embodiment, the vActRIIB
polypeptides are the mature versions, or the truncated mature versions of these sequences. As
used herein the term “mature VActRIIB polypeptide” refers to the polypeptide having the
amino acid signal sequence removed. In one embodiment, the mature sequences are, for
example, amino acids 19 through 160 of SEQ ID NO: 2, and amino acids 19 through 134 of
SEQ ID NO: 18, n one or both amino acids at ons 28 and 40 are substituted with
another non-native amino acid and the polypeptides retain the ability to bind to activin A,
myostatin, or GDF-l 1. As used herein the term truncated mature VActRIIB polypeptide refers
to the polypeptide having the signal sequence and in addition amino acids from the N-terminal
of the mature polypeptide removed. In one embodiment, the mature N-terminal 4 amino acids
or the N-terminal 6 amino acids of the mature polypeptide are d. In this embodiment,
the truncated mature sequences are, for example, amino acids 23 through 160 of SEQ ID NO:
2, or amino acids 25 through 160 of SEQ ID NO: 2; and amino acids 23 through 134 of SEQ
ID NO: 18, or amino acids 25 h 134 of SEQ ID NO: 18 wherein one or both amino acids
at positions 28 and 40 are tuted with non-wild type amino acids which retain the ability
to bind to activin A, tin, or GDF-l 1. As used herein, the term “position 28” and
“position 40” (that is, E28 and R40) refers to the amino acid position with reference to the
ces SEQ ID NOS: 2 and 18 that include an 18 amino acid signal sequence. For
consistency, if mature VActRIIB polypeptides have substitutions at position 10 and/or position
22, or ted mature polypeptides have substitutions at position 6 and/or position 18, or
substitutions at positions 4 and/or position 16 with respect to the mature or truncated mature
sequences, these variants will still be referred to with t to the fill length SEQ ID NOS: 2
and 18, or as shown in Figure l or 2, i.e., the amino acid substitution at position E28 and/or
R40. Such mature embodiments or N-terminal truncated embodiments are exemplified below.
2012/070571
In one embodiment, the substitution at position E28 is selected from the group
of amino acids consisting of W, Y and A. In one embodiment, the substitution at position 28 is
W. In a filrther embodiment the tution at position 28 is selected from the group of amino
acids consisting of A, F, Q, V, I, L, M, K, H, W and Y. In a filrther embodiment, the
substitution at position 40 is selected from the group of amino acids consisting of G, Q, M, H,
K and N. In a filrther embodiment the substitution at position 28 is selected from the group of
amino acids consisting of A, F, Q, V, I, L, M, K, H, W and Y and the substitution at position 40
is ed from the group of amino acids consisting of A, G, Q, M, H, K, and N. In one
embodiment, the protein comprises polypeptides having an amino acid sequence selected from
the group consisting of SEQ ID NOS: 4, 6, 8, 10, l2, l4, 16, 20, 22, 24, 26, 28, 30, 32, 34, 36,
38, 40, 42, 44, 46, 52, 54, 56, 60, 62, 64, 66, 68, 70, 72, 87, 88, 91, 93, 95, and 97. In another
embodiment, the protein comprises a ptide encoded by the polynucleotide having the
sequence set forth in the group consisting of SEQ ID NOS: 3, 5, 7, 9, ll, 13, 15, 19, 21, 23, 25,
27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 51, 53, 55, 59, 61, 63, 65, 67, 69, 71, 92, 94, 96 or its
complement.
In one embodiment, the signal sequences are removed from the vActRIIB
ptide, leaving the mature variant polypeptides. Various signal peptides can be used in
the preparation of the polypeptides of the instant application. The signal peptides can have the
sequence shown in Figures 1 and 2 (SEQ ID NO: 73), or alternative signal sequences such as
SEQ ID NO: 74, the signal sequence for SEQ ID NOS: 2 and 18. Any other signal peptides
useful for sing vActRIIB or vActRIIB5 polypeptides may be used.
In another ment, the vActRIIB polypeptides have sequences that are
substantially similar to SEQ ID NOS: 2 and 18. As used herein the term “substantially similar”
refers to polypeptides having at least about 80% identity, at least about 85% identity, at least
about 90% identity, at least about 95% identity, at least about 98% identity, or at least about
99% identity to the amino acid sequence set forth in SEQ ID NOS: 2 and 18, and wherein one
or both amino acids at positions 28 and/or 40 are substituted with non-wild type amino acids,
wherein the polypeptide retains the activity of the polypeptide of SEQ ID NOS: 2 and 18, that
is the ability to bind and inhibit myostatin, activin A or GDF-l 1. In addition, the term
vActRIIB ptide encompasses fragments of SEQ ID NOS: 2 or 18 such as N and C
terminal tions containing the tutions at position 28 and /or 40 described herein,
wherein the ptide is capable of binding and inhibiting myostatin, activin A or GDF-l l.
As used herein the term “derivative” of the IB and vActRIIB5
polypeptides refers to the ment of at least one additional chemical moiety, or at least one
WO 06175
additional polypeptide to form covalent or aggregate conjugates such as glycosyl groups, lipids,
acetyl groups, or C-terminal or N-terminal fusion polypeptides, conjugation to PEG molecules,
and other modifications which are bed more fully below. Variant ActRIIB receptor
ptides (vActRIIB) can also include additional modifications and derivatives, including
modifications to the C and N termini which arise from processing due to expression in various
cell types such as ian cells, E. coli, yeasts and other recombinant host cells. Further
included are vActRIIB polypeptide nts and polypeptides comprising inactivated N-
glycosylation site(s), inactivated protease processing site(s), or conservative amino acid
substitution(s), of the polypeptide sequences set forth in SEQ ID NOS: 4, 6, 8, 10, 12, l4, 16,
, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 52, 54, 56, 60, 62, 64, 66, 68, 70, 72, 87,
88, 91, 93, 95, and 97.
As used herein, the term a “vActRIIB or vActRIIBS polypeptide activity” or “a
biological activity of a soluble ActRIIB or ActRIIBS polypeptide” refers to one or more in vitro
or in vivo activities of the vActRIIB and vActRIIBS polypeptides including but not d to
those demonstrated in the Example below. Activities of the vActRIIB polypeptides include,
but are not limited to, the ability to bind to myostatin or activin A or GDF-l l, and the ability to
reduce or neutralize an activity of myostatin or n A or GDF-l 1. As used herein, the term
“capable of binding” to myostatin, activin A, or GDF-ll refers to binding measured by
methods known in the art, such as the Biacore method described in Example 2 below. Also, in
Example 2, the pMARE C2Cl2 cell-based assay measures n A neutralizing activity,
myostatin neutralizing activity, and GDF-ll neutralizing activity. In vivo activities e but
are not limited to increasing body weight, increasing lean muscle mass, increasing skeletal
muscle mass, decreasing fat mass as demonstrated in animal models below and as known in the
art. Biological activities further include reducing or preventing cachexia caused by certain
types of tumors, preventing the growth of certain types of tumors, and increasing survival of
certain animal models. Further discussion of the IB polypeptide activities is provided
below.
The polypeptides of the present invention further comprise heterologous
polypeptides attached to the vActRIIB polypeptide either directly or through a linker sequence
to form a fusion protein. As used herein the term “fusion protein” refers to a n having a
heterologous polypeptide attached via recombinant DNA techniques. logous
polypeptides include but are not limited to EC polypeptides, His tags, and leucine zipper
domains to promote erization and stabilization of the t ActRIIB ptides as
bed in, for example, WO 00/29581, which is herein orated by reference. In one
WO 06175 2012/070571
embodiment, the heterologous polypeptide is an EC ptide or domain. In one
embodiment, the Fc domain is selected from a human IgGl, IgG2, and IgG4 Fc domain. These
are provided in SEQ ID NOS: 80, 82 and 84. The vActRIIB can further comprise all or a
n of the hinge ce of the IgGl, IgG2, or IgG4 adjacent to its respective IgG Fc
region. The full hinge sequence for IgGl, IgG2, and IgG4 are provided in SEQ ID NOS: 76,
77, and 78 respectively.
[005 1] The vActRIIB polypeptide can optionally fiarther comprise a “linker” sequence.
Linkers serve primarily as a spacer between a polypeptide and a second heterologous
polypeptide or other type of fusion or between two or more variant ActRIIB polypeptides. In
one embodiment, the linker is made up of amino acids linked together by peptide bonds,
ably from 1 to 20 amino acids linked by peptide bonds, wherein the amino acids are
selected from the 20 naturally occurring amino acids. One or more of these amino acids may
be glycosylated, as is understood by those in the art. In one embodiment, the l to 20 amino
acids are selected from glycine, alanine, proline, asparagine, ine, and lysine. Preferably,
a linker is made up of a ty of amino acids that are sterically unhindered, such as glycine
and alanine. Exemplary linkers are polyglycines (particularly (Gly)5, (Gly)8, poly(Gly-Ala),
and polyalanines. One exemplary suitable linker as shown in the Examples below is (Gly)4Ser
(SEQ ID NO: 75). In a r embodiment, vActRIIB can comprise a hinge linker, that is a
linker sequence are provided adjacent to the hinge region, as exemplified in SEQ ID NO: 79.
The linkers are also non-peptide linkers. For example, alkyl linkers such as -
NH-(CH2)s-C(O)-, wherein s = 2-20 can be used. These alkyl linkers may further be
substituted by any non-sterically hindering group such as lower alkyl (e.g., Cl-C6) lower acyl,
halogen (e.g., Cl, Br), CN, NH2, phenyl, etc.
In one embodiment the vActRIIB polypeptides can be attached to an EC
polypeptide, directly or via a linker, or via a hinge linker. In one embodiment, the Fe is a
human IgG Fc. vActRIIB attached to Fe include for example, vActRIIB-IgGch, E28A (SEQ
ID NO: 60); vActRIIB-IgGch, E28W (SEQ ID NO: 62), vActRIIB-IgGch, E28Y (SEQ ID
NO: 64), vActRIIB-IgG Fc, R40G (SEQ ID NO: 66), vActRIIBS-IgGch, E28A (SEQ ID NO:
70), and IBS-IgGch E28W (SEQ ID NO: 72), as shown in Tables 1 and 2, and
described in the Examples herein. Further embodiments include vActRIIB-IgG2 Fc,
EQ ID NO: 91), vActRIIB-IgG2 Fc, E28Y (SEQ ID NO: 93), and vActRIIB-IgG2 Fc
(SEQ ID NO: 95). The variants have been demonstrated to produce less aggregation compared
to the wild type ActRIIB-IgG2 IgG2, as trated in the Examples below.
2012/070571
The vActRIIB polypeptides disclosed herein can also be attached to a non-
polypeptide molecule for the purpose of conferring desired properties such as reducing
degradation and/or increasing half-life, reducing toxicity, reducing immunogenicity, and/or
increasing the biological activity of the ActRIIB polypeptides. Exemplary molecules e
but are not limited to linear polymers such as polyethylene glycol (PEG), polylysine, a dextran;
a lipid; a cholesterol group (such as a steroid); a carbohydrate, or an accharide molecule.
[0 0 5 5] In another aspect, the present invention es ed nucleic acid molecules
comprising cleotides encoding the vActRIIB polypeptides of the present invention. As
used herein the term ted” refers to nucleic acid molecules purified to some degree from
endogenous material. In one embodiment, the nucleic acid molecule of the present invention
comprises a polynucleotide encoding the polypeptides of SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16,
,22,24,26,28,30,32,34,36,38,40,42,44,46,52,54,56,60,62,64,66,68,70,72,87,
88, 91, 93, 95, and 97. Due to the known degeneracy of the genetic code, wherein more than
one codon can encode the same amino acid, a DNA sequence can vary from that shown in SEQ
I[)}U)S:3,5,7,9,11,13,15,19,21,23,25,27,29,31,33,35,37,39,41,43,45,51,53,55,
59, 61, 63, 65, 67, 69, 71, 92, 94, and 96 or the mentary strand of SEQ ID NOS: 3, 5, 7,
9,11,13,15,19,21,23,25,27,29,31,33,35,37,39,41,43,45,51,53,55,59,61,63,65,67,
69, 71, 92, 94, and 96, and still encode a polypeptide having the amino acid sequence of SEQ
I[)}M)S:4,6,8,10,12,14,16,20,22,24,26,28,30,32,34,36,38,40,42,44,46,52,54,56,
60,62,64,66,68,70,72,87,88,91,93,95,andl¥1 SudivafiantDDLAsequencescaniesuh
from silent mutations occurring during production, or can be the product of deliberate
nnuagenesnsofthesesequences
In another embodiment the nucleic acid molecule of the present invention
comprises a polynucleotide having the cleotide sequence set forth in SEQ ID NOS: 3, 5,
7,9,11,13,15,19,21,23,25,27,29,31,33,35,37,39,41,43,45,51,53,55,59,61,63,65,
67, 69, 71, 92, 94, and 96 or the complementary strand of SEQ ID NOS: 3, 5, 7, 9, 11, 13, 15,
19,21,23,25,27,29,31,33,35,37,39,41,43,45,51,53,55,59,61,63,65,67,69,71,92,
94, and 96. In another embodiment, the present invention provides nucleic acid molecules
which hybridize under stringent or moderate ions with the polypeptide-encoding regions
ofSEKQI[)}M)S:3,5,7,9,11,13,15,19,21,23,25,27,29,31,33,35,37,39,41,43,45,51,
53,55,59,61,63,65,67,69,71,92,94,and96\Nhemfintheencodedpoqupfideconqwmesan
amino acid sequence as set forth in SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16, 20, 22, 24, 26, 28, 30,
36,38,40,42,44,46,52,54,56,60,62,64,66,68,70,72,87,88,91,93,95,and97
and n the encoded polypeptide maintains an activity of a vActRIIB polypeptide.
c acid molecules of the invention include DNA in both -stranded
and double-stranded form, as well as the RNA complement f. DNA includes, for
example, cDNA, genomic DNA, synthetic DNA, DNA amplified by PCR, and combinations
f. Genomic DNA may be isolated by conventional techniques, such as by using the DNA
of SEQ ID NOS:l or 17, or a suitable nt thereof, as a probe. Genomic DNA encoding
ActRIIB polypeptides is obtained from genomic libraries which are available for a number of
species. Synthetic DNA is available from chemical synthesis of overlapping oligonucleotide
fragments ed by assembly of the nts to reconstitute part or all of the coding
regions and flanking sequences. RNA may be obtained from procaryotic expression vectors
which direct high-level synthesis ofmRNA, such as vectors using T7 promoters and RNA
polymerase. cDNA is obtained from libraries prepared from mRNA isolated from various
tissues that express ActRIIB. The DNA molecules of the ion include filll length genes as
well as polynucleotides and fragments thereof The full length gene may also include
sequences encoding the N-terminal signal ce.
In another aspect of the present invention, expression vectors containing the
nucleic acid sequences are also ed, and host cells transformed with such vectors and
s of producing the vActRIIB polypeptides are also provided. The term “expression
vector” refers to a plasmid, phage, virus or vector for expressing a polypeptide from a
polynucleotide ce. Vectors for the sion of the vActRIIB ptides contain at a
minimum ces required for vector propagation and for expression of the cloned insert.
An sion vector comprises a transcriptional unit comprising an assembly of (l) a genetic
element or elements having a regulatory role in gene expression, for example, promoters or
enhancers, (2) a sequence that encodes vActRIIB polypeptides to be transcribed into mRNA
and translated into protein, and (3) appropriate transcription initiation and termination
sequences. These sequences may fiarther include a selection marker. s suitable for
expression in host cells are readily available and the nucleic acid molecules are inserted into the
vectors using standard recombinant DNA ques. Such vectors can include promoters
which filnction in specific tissues, and viral vectors for the expression of vActRIIB in targeted
human or animal cells. An exemplary expression vector suitable for expression of vActRIIB is
the pDSRa, (described in W0 90/14363, herein incorporated by reference) and its derivatives,
containing vActRHB polynucleotides, as well as any additional suitable vectors known in the
art or described below.
The application further provides methods of making vActRHB polypeptides. A
variety of other expression/host systems may be utilized. These systems include but are not
limited to microorganisms such as bacteria ormed with recombinant bacteriophage,
plasmid or cosmid DNA expression vectors; yeast ormed with yeast expression vectors;
insect cell systems infected with virus sion vectors (e.g., baculovirus); plant cell systems
transfected with virus expression s (e.g., ower mosaic virus, CaMV; o
mosaic virus, TMV) or transformed with bacterial sion vectors (e.g., Ti or pBR322
plasmid); or animal cell systems. Mammalian cells useful in recombinant protein production
include but are not limited to VERO cells, HeLa cells, Chinese hamster ovary (CHO) cell lines,
or their derivatives such as Veggie CH0 and related cell lines which grow in serum-free media
(see Rasmussen et al., 1998, Cytotechnology 28:31) or CHO strain DX-B11, which is deficient
in DHFR (see Urlaub et al., 1980, Proc. Natl. Acad. Sci. USA 77:4216-20) COS cells such as
the COS-7 line ofmonkey kidney cells (ATCC CRL 1651) (see Gluzman et al., 1981, Cell
23:175), W138, BHK, HepG2, 3T3 (ATCC CCL 163), RIN, MDCK, A549, PC12, K562, L
cells, C127 cells, BHK (ATCC CRL 10) cell lines, the CV1/EBNA cell line derived from the
African green monkey kidney cell line CV1 (ATCC CCL 70) (see McMahan et al., 1991,
EMBO J. 10:2821), human embryonic kidney cells such as 293, 293 EBNA or MSR 293,
human epidermal A431 cells, human Colo205 cells, other transformed primate cell lines,
normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary
explants, HL-60, U937, HaK or Jurkat cells. Mammalian expression allows for the production
of secreted or soluble polypeptides which may be recovered from the growth medium.
Using an appropriate host-vector system, vActRIIB polypeptides are produced
recombinantly by culturing a host cell transformed with an expression vector ning the
nucleic acid molecules of the present invention under conditions allowing for production.
Transformed cells can be used for long-term, high-yield polypeptide production. Once such
cells are transformed with vectors that contain selectable markers as well as the desired
expression cassette, the cells can be allowed to grow for 1-2 days in an enriched media before
they are switched to selective media. The selectable marker is designed to allow growth and
recovery of cells that successfully express the uced sequences. Resistant clumps of stably
transformed cells can be proliferated using tissue culture techniques appropriate to the cell line
employed. An overview of expression of recombinant proteins is found in Methods of
Enzymology, v. 185, Goeddell, D.V., ed., Academic Press (1990).
[006 1] In some cases, such as in expression using procaryotic systems, the expressed
polypeptides of this ion may need to be “refolded” and ed into a proper tertiary
structure and 1de linkages generated in order to be biologically active. Refolding can be
accomplished using a number of procedures well known in the art. Such methods include, for
example, exposing the solubilized polypeptide to a pH usually above 7 in the presence of a
chaotropic agent. The ion of chaotrope is similar to the choices used for inclusion body
solubilization, however a chaotrope is typically used at a lower concentration. Exemplary
opic agents are guanidine and urea. In most cases, the refolding/oxidation solution will
also contain a reducing agent plus its oxidized form in a specific ratio to generate a particular
redox potential which allows for disulfide shuffling to occur for the formation of cysteine
bridges. Some ly used redox couples include cysteine/cystamine,
glutathione/dithiobisGSH, cupric chloride, dithiothreitol DTT/dithiane DTT, and 2-
mercaptoethanol (bME)/dithio-bME. In many instances, a vent may be used to increase
the efficiency of the ing. Commonly used cosolvents e glycerol, polyethylene
glycol of various molecular weights, and arginine.
In addition, the polypeptides can be synthesized in solution or on a solid support
in accordance with conventional techniques. Various automatic synthesizers are commercially
available and can be used in accordance with known ols. See, for example, Stewart and
Young, Solid Phase Peptide Synthesis, 2d.Ed., Pierce Chemical Co. (1984); Tam et al., J Am
Chem Soc, 42, (1983); eld, Science 232:341-347 (1986); Barany and eld,
The Peptides, Gross and Meienhofer, eds, ic Press, New York, 1-284; Barany et al., Int
J Pep Protein Res, 30:705-739 (1987).
The polypeptides and proteins of the present invention can be d according
to n ation techniques are well known to those of skill in the art. These ques
involve, at one level, the crude fractionation of the proteinaceous and non-proteinaceous
fractions. Having separated the peptide polypeptides from other proteins, the peptide or
polypeptide of interest can be further purified using chromatographic and electrophoretic
techniques to achieve partial or complete purification (or ation to homogeneity). The
term “isolated polypeptide” or “purified polypeptide” as used herein, is intended to refer to a
composition, isolatable from other components, wherein the ptide is purified to any
degree relative to its naturally-obtainable state. A purified polypeptide therefore also refers to a
polypeptide that is free from the environment in which it may naturally occur. Generally,
“purified” will refer to a polypeptide composition that has been subjected to fractionation to
remove various other components, and which composition substantially retains its expressed
biological activity. Where the term “substantially purified” is used, this designation will refer
to a peptide or polypeptide composition in which the polypeptide or peptide forms the major
component of the composition, such as constituting about 50%, about 60%, about 70%, about
80%, about 85%, or about 90% or more of the proteins in the composition.
2012/070571
Various techniques suitable for use in purification will be well known to those
of skill in the art. These include, for example, itation with ammonium sulphate, PEG,
antibodies oprecipitation) and the like or by heat denaturation, followed by
centrifugation; tography such as affinity chromatography in-A columns), ion
exchange, gel filtration, reverse phase, hydroxylapatite, hydrophobic interaction
chromatography; isoelectric focusing; gel electrophoresis; and combinations of these
techniques. As is generally known in the art, it is believed that the order of conducting the
various purification steps may be changed, or that certain steps may be omitted, and still result
in a le method for the preparation of a substantially purified polypeptide. Exemplary
purification steps are provided in the Examples below.
Various methods for quantifying the degree of purification of polypeptide will
be known to those of skill in the art in light of the present disclosure. These include, for
example, determining the specific binding activity of an active fraction, or assessing the
amount of peptide or polypeptide within a fraction by SDS/PAGE analysis. A preferred
method for assessing the purity of a polypeptide fiaction is to calculate the binding ty of
the n, to compare it to the g activity of the initial extract, and to thus calculate the
degree of purification, herein assessed by a “-fold purification number.” The actual units used
to represent the amount of binding activity will, of course, be dependent upon the particular
assay que chosen to follow the ation and whether or not the polypeptide or peptide
exhibits a detectable binding ty.
t activin type IIB polypeptides bind to ligands that activate -
degradation cascades. vActRIIB polypeptides capable of binding and inhibiting the activity of
the ligands activin A, myostatin, and/or GDF-l l, have therapeutic potential against the diseases
that involve muscle atrophy, as well as the ent of certain cancers, e.g. ovarian tumors
prostate tumors and melanoma, and other diseases as shown in the Examples below.
[0 0 6 7] However, aggregation can occur when expressing or purifying wild-type
ActRIIB or ActRHBS polypeptides. This aggregation includes structured oligomer formation
during expression and non-structured aggregate generation both during expression and after
polypeptide purification.
The combined approaches of structure analysis, molecular modeling, and mass
spectrometry have indicated that multimerization may arise in ActRIIB polypeptides via
olecular disulfide bond formation aided by electrostatic and hydrogen bonding
interactions between nonglycosylated ActRIIB polypeptides. cant hydrogen bonds exist
at the interface of two ActRIIB molecules; between E28 side chain in one ActRIIB and R40
side chain in the other ActRIIB, for example. In addition, critical electrostatic interactions exist
between E28 in one B and R40 in the other B.
These electrostatic interactions may significantly contribute to increase the
tion of temporal B dimers, resulting in promotion of noncovalent and/or covalent
bond formation between ActRIIB units. The interaction between residues 28 and 40 is the most
critical among these interactions as these two residues are involved in double hydrogen bonds
and a strong electrostatic interaction. The residues 28 and 40 are involved in ActRIIB:ActRIIB
interactions and not in ActRIIB:ligand ctions. Thus, residues 28 and 40 can be
substituted with tive amino acids according to invention, to improve the lity, and
reduce the aggregation of the receptor polypeptides. Therefore, E28 and R40 were substituted
respectively with other possible natural amino acids, sed, and tested by Biacore as shown
below. Biacore determined binding are shown in Tables 1A and 1B in Example 2 below.
Furthermore, percent aggregation of the vActRIIB polypeptides are determined below.
The results in the Examples below show reduced ation for vActRIIB
polypeptides and proteins having the amino acid substitutions described , while retaining
the ability to bind and neutralize myostatin, activin A, or GDF-l 1.
ANTIBODIES
[007 1] The present invention filrther includes antibodies which bind to variant ActRIIB
polypeptides, including those that specifically bind to the vActRIIB polypeptides of the present
invention. As used herein the term “specifically binds” refers to antibodies having a binding
affinity (Ka) for vActRIIB polypeptides of 106 M-l or greater. As used herein, the term
“antibody” refers to intact antibodies including polyclonal antibodies (see, for example
Antibodies: A Laboratory Manual, Harlow and Lane (eds), Cold Spring Harbor Press, (1988)),
and onal antibodies (see, for example, US. Patent Nos. RE 32,011, 4,902,614,
4,543,439, and 4,411,993, and Monoclonal Antibodies: A New Dimension in Biological
Analysis, Plenum Press, Kennett, McKeam and Bechtol (eds.) (1980)). As used herein, the
term “antibody” also refers to a fragment of an antibody such as F(ab), F(ab’), F(ab’)2, Fv, Fe,
and single chain antibodies which are produced by recombinant DNA techniques or by
enzymatic or al cleavage of intact dies. The term “antibody” also refers to
bispecific or bifunctional antibodies, which are an artificial hybrid antibody having two
ent heavy/light chain pairs and two different binding sites. Bispecific antibodies can be
produced by a variety of s including fusion of hybridomas or linking of Fab’ fragments.
(See Songsivilai et al, Clin. Exp. Immunol. 79:315-321 (1990), ny et al., J.
Immunol. 148: 1547-1553 (1992)).
As used herein the term “antibody” also refers to chimeric antibodies, that is,
antibodies having a human constant dy globin domain coupled to one or more
man le antibody immunoglobin domain, or fragments f (see, for example,
US. Patent No. 5,595,898 and US. Patent No. 5,693,493). Antibodies also refers to
“humanized” antibodies (see, for example, US. Pat. No. 567 and W0 94/10332),
minibodies (WO 94/09817), maxibodies, and antibodies produced by transgenic animals, in
which a transgenic animal containing a proportion of the human antibody producing genes but
deficient in the production of endogenous antibodies are capable of producing human
antibodies (see, for example, Mendez et al., Nature Genetics 15:146-156 (1997), and US.
Patent No. 6,300,129). The term odies” also includes multimeric dies, or a higher
order complex of proteins such as heterdimeric antibodies, and anti-idiotypic antibodies.
“Antibodies” also includes anti-idiotypic antibodies. The antibodies against V ActRIIB can be
used, for example, to identify and quantitate vActRIIB in vitro and in vivo.
Also ed are polyclonal antibodies from any mammal, for example mouse
and rat antibodies, and rabbit antibodies, that bind specifically to the vActRIIB polypeptides
described , including SEQ ID NOS: 4, 6, 8, 10, 12, l4, 16, 20, 22, 24, 26, 28, 30, 32, 34,
36, 38, 40, 42, 44, 46, 52, 54, 56, 60, 62, 64, 66, 68, 70, 72, 87, 88, 91, 93, 95, and 97.
Such antibodies find use as research tools and in quantitative assays for
detecting and assaying the polypeptides disclosed herein. Such antibodies are made using
methods described above and as known in the art.
PHARMACEUTICAL COMPOSITIONS
Pharmaceutical compositions containing the vActRIIB proteins and
polypeptides of the present invention are also provided. Such compositions comprise a
therapeutically or prophylactically effective amount of the polypeptide or protein in admixture
with ceutically acceptable materials, and physiologically acceptable formulation
materials. The pharmaceutical composition may contain formulation materials for modifying,
maintaining or ving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity,
odor, sterility, stability, rate of dissolution or release, tion or penetration of the
composition. Suitable formulation materials include, but are not limited to, amino acids (such
as glycine, glutamine, asparagine, ne or lysine); crobials; antioxidants (such as
ascorbic acid, sodium sulfite or sodium hydrogen-sulfite); buffers (such as borate, bicarbonate,
Tris-HCl, citrates, phosphates, other organic acids); bulking agents (such as ol or
glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)); complexing
agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or ypropyl-beta-
cyclodextrin); fillers; monosaccharides; disaccharides and other carbohydrates (such as
glucose, mannose, or dextrins); proteins (such as serum albumin, gelatin or immunoglobulins);
coloring; flavoring and diluting agents; emulsifying ; hydrophilic polymers (such as
polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as
sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal,
phenethyl l, methylparaben, propylparaben, chlorhexidine, sorbic acid or en
peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols
(such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as
pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate 80, triton,
tromethamine, lecithin, cholesterol, tyloxapal); stability ing agents (sucrose or ol);
tonicity enhancing agents (such as alkali metal halides (preferably sodium or potassium
chloride, mannitol sorbitol); ry vehicles; diluents; excipients and/or pharmaceutical
adjuvants. (Remington’s Pharmaceutical Sciences, 18th Edition, A.R. Gennaro, ed., Mack
Publishing Company, 1990).
The optimal pharmaceutical composition will be determined by one d in
the art depending upon, for example, the intended route of administration, ry format, and
desired dosage. See for example, Remington’s Pharmaceutical Sciences, supra. Such
compositions may influence the physical state, stability, rate of in vivo e, and rate of in
vivo clearance of the polypeptide. For e, suitable compositions may be water for
injection, physiological saline solution for parenteral administration.
The primary vehicle or carrier in a ceutical composition may be either
aqueous or non-aqueous in nature. For example, a le vehicle or carrier may be water for
injection, physiological saline solution or artificial cerebrospinal fluid, possibly mented
with other materials common in compositions for parenteral administration. l buffered
saline or saline mixed with serum albumin are further exemplary vehicles. Other exemplary
pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of
about pH 4.0-5.5, which may fiarther include sorbitol or a suitable substitute thereof In one
embodiment of the t invention, compositions may be prepared for storage by mixing the
selected composition having the desired degree of purity with optional formulation agents
(Remington’s Pharmaceutical Sciences, supra) in the form of a lyophilized cake or an aqueous
2012/070571
solution. Further, the therapeutic composition may be formulated as a lyophilizate using
appropriate excipients such as sucrose.
The formulations can be delivered in a variety of methods, for example, by
inhalation therapy, orally, or by ion. When parenteral administration is contemplated, the
therapeutic compositions for use in this invention may be in the form of a pyrogen-free,
parenterally acceptable aqueous on comprising the desired polypeptide in a
pharmaceutically acceptable vehicle. A particularly le vehicle for eral injection is
sterile distilled water in which a polypeptide is formulated as a sterile, isotonic solution,
properly preserved. Yet another preparation can involve the ation of the d
le with an agent, such as injectable microspheres, bio-erodible particles, polymeric
compounds (polylactic acid, polyglycolic acid), beads, or liposomes, that provides for the
lled or sustained e of the product which may then be delivered via a depot
injection. Hyaluronic acid may also be used, and this may have the effect of promoting
sustained duration in the circulation. Other suitable means for the introduction of the desired
molecule include implantable drug delivery devices.
In another aspect, pharmaceutical formulations suitable for injectable
administration may be formulated in aqueous solutions, preferably in logically
compatible buffers such as Hanks’ solution, Ringer’s solution, or physiologically buffered
saline. Aqueous injection suspensions may contain substances that increase the viscosity of the
suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally,
suspensions of the active compounds may be prepared as appropriate oily injection
sions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or
synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid
tionic amino polymers may also be used for delivery. Optionally, the suspension may
also contain suitable stabilizers or agents to increase the lity of the compounds and allow
for the preparation of highly concentrated solutions. In another embodiment, a pharmaceutical
composition may be formulated for inhalation. Inhalation solutions may also be formulated
with a propellant for aerosol delivery. In yet another embodiment, solutions may be nebulized.
Pulmonary administration is further described in PCT Application No. PCT/U894/001875,
which describes pulmonary delivery of chemically modified proteins.
It is also contemplated that certain formulations may be stered orally. In
one embodiment of the present invention, molecules that are administered in this fashion can be
formulated with or without those carriers customarily used in the compounding of solid dosage
forms such as s and capsules. For example, a e may be ed to release the
active portion of the formulation at the point in the gastrointestinal tract when bioavailability is
maximized and pre-systemic degradation is minimized. Additional agents can be included to
facilitate tion of the therapeutic molecule. Diluents, ngs, low melting point
waxes, vegetable oils, lubricants, suspending agents, tablet egrating agents, and binders
may also be employed. Pharmaceutical compositions for oral administration can also be
formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable
for oral administration. Such carriers enable the pharmaceutical compositions to be formulated
as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, sions, and the like, for
ingestion by the patient.
[008 1] Pharmaceutical preparations for oral use can be ed through combining
active compounds with solid excipient and sing the resultant mixture of granules
(optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added,
if desired. Suitable ents include carbohydrate or protein fillers, such as sugars, including
lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants;
cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium
carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin
and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-
linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.
Dragee cores may be used in conjunction with suitable coatings, such as
concentrated sugar ons, which may also contain gum arabic, talc, polyvinylpyrrolidone,
carbopol gel, polyethylene glycol, and/or um dioxide, lacquer solutions, and suitable
organic solvents or solvent mixtures. Dyestuffs or ts may be added to the tablets or
dragee coatings for product fication or to characterize the quantity of active compound,
i.e., .
Pharmaceutical preparations that can be used orally also include push-fit
capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as
ol or sorbitol. Push-fit capsules can contain active ients mixed with fillers or
binders, such as lactose or starches, lubricants, such as talc or ium stearate, and,
optionally, stabilizers. In soft capsules, the active compounds may be ved or suspended in
suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without
stabilizers.
Additional pharmaceutical compositions will be evident to those skilled in the
art, including formulations ing polypeptides in sustained- or controlled-delivery
formulations. Techniques for formulating a variety of other sustained- or controlled-delivery
2012/070571
means, such as liposome carriers, bio-erodible microparticles or porous beads and depot
injections, are also known to those skilled in the art. See for example, PCT/US93/00829 that
describes controlled release of porous polymeric microparticles for the delivery of
pharmaceutical compositions. Additional examples of sustained-release preparations include
semipermeable polymer matrices in the form of shaped es, e. g. films, or microcapsules.
Sustained release es may include polyesters, hydrogels, polylactides (US. 3,773,919, EP
58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al.,
Biopolymers, 22:547-556 (1983), poly (2-hydroxyethyl-methacrylate) (Langer et al., J.
Biomed. Mater. Res., 15:167-277, (1981); Langer et al., Chem. Tech.,12:98-105(1982)),
ne vinyl acetate (Langer et al., supra) or poly-D(-)hydroxybutyric acid (EP 133,988).
Sustained-release compositions also include liposomes, which can be prepared by any of
l methods known in the art. See e.g., Eppstein et al., PNAS (USA), 823688 ; EP
36,676; EP 88,046; EP 143,949.
[0 0 8 5] The pharmaceutical composition to be used for in vivo stration typically
must be sterile. This may be accomplished by filtration through sterile filtration nes.
Where the composition is lyophilized, sterilization using this method may be conducted either
prior to or following lyophilization and reconstitution. The ition for parenteral
administration may be stored in lyophilized form or in solution. In addition, parenteral
compositions generally are placed into a container having a sterile access port, for example, an
intravenous solution bag or vial having a stopper able by a hypodermic injection needle.
Once the pharmaceutical composition has been formulated, it may be stored in
sterile vials as a solution, suspension, gel, emulsion, solid, or a dehydrated or lyophilized
powder. Such formulations may be stored either in a ready-to-use form or in a form (e.g.,
lyophilized) requiring reconstitution prior to administration.
In a specific embodiment, the present invention is directed to kits for producing
a single-dose administration unit. The kits may each contain both a first container having a
dried n and a second container having an aqueous formulation. Also included within the
scope of this invention are kits containing single and multi-chambered pre-filled syringes (e.g.,
liquid syringes and lyosyringes).
An effective amount of a pharmaceutical composition to be ed
therapeutically will depend, for example, upon the eutic context and objectives. One
skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary
ing, in part, upon the molecule delivered, the indication for which the polypeptide is
being used, the route of administration, and the size (body weight, body surface or organ size)
and condition (the age and general health) of the patient. ingly, the clinician may titer
the dosage and modify the route of administration to obtain the optimal therapeutic . A
typical dosage may range from about 0.1mg/kg to up to about 100 mg/kg or more, depending
on the factors mentioned above. Polypeptide compositions may be preferably injected or
administered intravenously. Long-acting pharmaceutical compositions may be administered
every three to four days, every week, or biweekly depending on the half-life and clearance rate
of the particular formulation. The frequency of dosing will depend upon the pharmacokinetic
parameters of the polypeptide in the formulation used. Typically, a composition is
administered until a dosage is reached that achieves the desired effect. The composition may
therefore be administered as a single dose, or as multiple doses (at the same or different
concentrations/dosages) over time, or as a continuous infusion. Further refinement of the
appropriate dosage is routinely made. Appropriate dosages may be ascertained through use of
appropriate dose-response data.
The route of administration of the ceutical composition is in accord with
known s, e.g. orally, through injection by intravenous, intraperitoneal, intracerebral
(intra-parenchymal), intracerebroventricular, intramuscular, intra-ocular, intraarterial,
intraportal, intralesional routes, intramedullary, intrathecal, entricular, transdermal,
subcutaneous, or intraperitoneal; as well as intranasal, l, topical, sublingual, urethral,
vaginal, or rectal means, by sustained release systems or by implantation devices. Where
desired, the itions may be administered by bolus injection or continuously by infusion,
or by implantation device. Alternatively or additionally, the ition may be administered
locally via implantation of a membrane, sponge, or another appropriate al on to which
the desired molecule has been absorbed or encapsulated. Where an implantation device is used,
the device may be implanted into any le tissue or organ, and ry of the desired
le may be via diffiJsion, timed-release bolus, or continuous administration.
In some cases, the vActRIIB polypeptides of the present invention can be
delivered by implanting certain cells that have been genetically engineered, using s such
as those described herein, to express and secrete the polypeptide. Such cells may be animal or
human cells, and may be autologous, heterologous, or xenogeneic. Optionally, the cells may be
immortalized. In order to decrease the chance of an immunological response, the cells may be
encapsulated to avoid infiltration of surrounding tissues. The encapsulation als are
typically biocompatible, semi-permeable polymeric ures or membranes that allow the
release of the polypeptide product(s) but prevent the destruction of the cells by the patient’s
immune system or by other detrimental s from the nding tissues.
[009 1] vActRIIB gene therapy in vivo is also envisioned wherein a nucleic acid
molecule ng vActRIIB, or a derivative of vActRIIB is introduced directly into the
subject. For example, a nucleic acid sequence encoding a vActRIIB is introduced into target
cells via local injection of a c acid construct with or without an appropriate delivery
vector, such as an adeno-associated virus vector. Alternative viral vectors include, but are not
limited to, retroviruses, adenovirus, herpes simplex, virus and papilloma virus vectors.
Physical er of the virus vector may be achieved in vivo by local injection of the desired
c acid construct or other appropriate delivery vector containing the desired nucleic acid
sequence, liposome-mediated transfer, direct injection (naked DNA), or microparticle
bombardment (gene-gun).
USES OF vActRIIB COMPOSITIONS
The present invention provides methods and pharmaceutical compositions for
reducing or neutralizing the amount or activity of myostatin, activin A, or GDF-ll in vivo and
in vitro by contacting the polypeptides with IB polypeptide. vActRIIB polypeptides
have a high affinity for myostatin, activin A, and GDF-l l, and are capable of reducing and
inhibiting the biological activities of at least one of myostatin, n A and GDF-l 1. In some
embodiments, the vActRIIB polypeptides exhibit improved activity compared with the wild
type ActRIIB polypeptides. This is demonstrated in the Examples below.
In one aspect, the present ion provides methods and reagents for ng
myostatin-related and/or activin A related disorders in a subject in need of such a treatment by
stering an effective dosage of a vActRIIB ition to the subject. As used herein the
term “subject” refers to any animal, such as mammals including humans.
The compositions of the present invention are used to increase lean muscle mass
as a percentage of body weight and decrease fat mass as percentage of body weight.
The disorders that can be d by a vActRIIB ition include but are not
limited to various forms of muscle wasting, as well as metabolic disorders such as diabetes and
related ers, and bone degenerative diseases such as osteoporosis. The vActRIIB
itions have been demonstrated to be effective in treating muscle wasting disorders in
various disease models set forth in Example 3 below. This demonstrated in the treatment of
muscle wasting in inhibin-(x knockout mice, treatment of muscle wasting in 26 cancer
ia models, prevention of muscular atrophy in hind limb suspension model, treatment of
OXV female showing increase in lean muscle mass, decrease in fat mass and increase in bone
mineral content.
Muscle wasting disorders also include phies such as Duchenne’s ar
dystrophy, progressive muscular dystrophy, Becker’s type muscular dystrophy, Dej erine-
Landouzy muscular dystrophy, Erb’s muscular dystrophy, and infantile neuroaxonal muscular
dystrophy. Additional muscle wasting disorders arise from chronic diseases or disorders such
as amyotrophic lateral sclerosis, congestive obstructive pulmonary disease, cancer, AIDS, renal
failure, organ atrophy, androgen deprivation, and rheumatoid tis.
Over-expression of myostatin and/or activin may bute to cachexia, a
severe muscle and fat wasting syndrome. The effectiveness of the vActRIIB polypeptides in
treating cachexias in animal models is shown in Example 3 below. Cachexia also arises due to
rheumatoid arthritis, diabetic nephropathy, renal failure, chemotherapy, injury due to burns, as
well as other causes. In another e, serum and intramuscular trations of
myostatin-immunoreactive protein was found to be increased in men exhibiting AIDS-related
muscle wasting and was inversely d to fat-free mass (Gonzalez-Cadavid et al., PNAS
USA 95: 1493 8-14943 (1998)). Myostatin levels have also been shown to increase in response
to burns es, resulting in a catabolic muscle effect (Lang et al, FASEB J 15, 1807-1809
(2001)). Additional conditions resulting in muscle wasting may arise from inactivity due to
disability such as confinement in a wheelchair, prolonged bed rest due to stroke, illness, spinal
chord injury, bone fracture or trauma, and muscular atrophy in a microgravity nment
(space flight). For example, plasma myostatin immunoreactive protein was found to increase
after ged bed rest (Zachwiej a et al. J Gravit Physiol. 6(2): 1 l(l999). It was also found
that the muscles of rats exposed to a microgravity environment during a space e flight
expressed an increased amount of tin compared with the muscles of rats which were not
exposed (Lalani et al., J.Endocrin 167 (3):417-28 (2000)).
In addition, age-related increases in fat to muscle ratios, and age-related
muscular y appear to be related to myostatin. For example, the average serum myostatin-
immunoreactive protein increased with age in groups of young (19-35 yr old), middle-aged (3 6-
75 yr old), and elderly (76-92 yr old) men and women, while the average muscle mass and fat-
free mass declined with age in these groups (Yarasheski et al. J Nutr Aging 6(5):343-8 (2002)).
In addition, myostatin has now been found to be sed at low levels in heart muscle and
expression is lated in cardiomyocytes after infarct (Sharma et al., J Cell Physiol. 180
(1): 1-9 (1999)). Therefore, reducing myostatin levels in the heart muscle may improve
recovery of heart muscle after infarct.
Myostatin also appears to influence lic disorders including type 2
diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, and y. For example,
lack of myostatin has been shown to improve the obese and diabetic phenotypes of two mouse
models (Yen et al. FASEB J. 8:479 . It has been demonstrated in US. application serial
no: 1 1/590,962, US. application publication No: 2007/01 17130, AAV-ActRIIBS vectors
increases the muscle to fat ratio in an animal, in particular for obese animal models. The
vActRIIB polypeptides of the present disclosure, such as SEQ ID NOS: 4, 6, 8, 10, 12, 14, 16,
, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 52, 54, 56, 60, 62, 64, 66, 68, 70, 72, 87,
88, 91, 93, 95 are suitable for such uses. Therefore, decreasing fat composition by
administering the compositions of the present invention will e diabetes, y, and
hyperglycemic conditions in animals. In addition, compositions containing the vActRIIB
polypeptides may decrease food intake in obese individuals, as demonstrated in US.
application serial no: 1 1/590,962, US. ation publication No: 2007/01 17130 for the
ActRIIBS polypeptide.
[0 0 1 0 0] Administering the ActRIIB polypeptides of the present invention may improve
bone strength and reduce osteoporosis and other degenerative bone diseases. This has been
demonstrated in the OVX mouse model described below. It has been also been found, for
example, that myostatin-deficient mice showed increased mineral content and y of the
mouse humerus and increased mineral content of both trabecular and cortical bone at the
regions where the muscles , as well as increased muscle mass (Hamrick et al. Calcif
Tissue Int 71(1):63-8 (2002)). In addition, the vActRIIB compositions of the present invention
can be used to treat the effects of androgen ation such as androgen deprivation therapy
used for the treatment of prostate cancer.
[00 1 0 1] The present invention also provides methods and compositions for increasing
muscle mass in food animals by administering an effective dosage of the vActRIIB proteins to
the animal. Since the mature C-terminal tin polypeptide is identical in all species tested,
vActRIIB polypeptides would be ed to be effective for increasing muscle mass and
reducing fat in any agriculturally important species including cattle, chicken, turkeys, and pigs.
[00 1 02] The vActRIIB polypeptides and itions of the present invention also
antagonize the activity of activin A. n A is known to be expressed in certain types of
cancers, particularly gonadal tumors such as ovarian carcinomas, and to cause severe cachexia.
(Ciprano et al. Endocrinol 141 (7):2319-27 (2000), Shou et al., Endocrinol 138 (11):5000-5
(1997); Coerver et al, Mol inol 10(5):534-43 (1996); Ito et al. British J Cancer
82(8): 1415-20 (2000), Lambert-Messerlian, et al, logic Oncology 74:93-7 (1999). In
Example 3 below, the vActRIIB ptides of the present invention have been demonstrated
to be effective in treating severe ia, reducing tumor size, and prolonging survival in
WO 06175
inhibin-u knockout mice models and colon-26 cancer cachexia mouse models. Therefore, the
compositions of the present disclosure can be used to treat conditions related to activin A
overexpression, as well as myostatin expression, such as cachexia from certain cancers and the
treatment of certain gonadal type tumors and melanoma.
[00 1 03] The compositions of the present disclosure may be used alone or in combination
with other therapeutic agents to enhance their therapeutic effects or decrease ial side
effects. These properties include increased activity, increased solubility, reduced degradation,
increased half-life, reduced toxicity, and reduced immunogenicity. Thus the compositions of
the t disclosure are useful for extended treatment s. In addition, the properties of
hydrophilicity and hydrophobicity of the compounds of the invention are well balanced,
thereby ing their utility for both in vitro and especially in vivo uses. Specifically,
compounds of the disclosure have an appropriate degree of solubility in aqueous media that
permits absorption and ilability in the body, while also having a degree of lity in
lipids that permits the compounds to traverse the cell membrane to a putative site of action,
such as a particular muscle mass.
[00 1 04] The vActRIIB polypeptides and itions of the present invention can be
used in ation with herapeutic agents for treating . Chemotherapeutics can
include anti-neoplastic drugs. herapeutics can also include alkylating agents, anti-
metabolites, plant alkaloids and terpenoids.
[00 1 05] Alkylating agents can comprise cisplatin and caroplatin. Anti-metabolites can
include purines (e. g. azathiprine or mercaptopurine) or pyrimidines. Additionally, chemo-
therapeutic agents can be nucleoside analogues, e.g. 5-fluorocil. Vinca alkaloids, such as
vincristine or vinblastine can also be used.
[00 1 0 6] Additional anti-neoplastic agents can include, for example, alkylating agents
including: nitrogen mustards, such as mechlorethamine, cyclophosphamide, ifosfamide,
melphalan and chlorambucil; oureas, such as carmustine (BCNU), lomustine (CCNU),
and semustine (methyl-CCNU); ethylenimines/methylmelamine such as thriethylenemelamine
(TEM), triethylene, thiophosphoramide (thiotepa), hexamethylmelamine (HMM, altretamine);
alkyl sulfonates such as an; triazines such as dacarbazine ; antimetabolites
including folic acid analogs such as methotrexate and trimetrexate, pyrimidine analogs such as
S-fluorouracil, fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-
azacytidine, 2,2’-difluorodeoxycytidine, purine analogs such as 6-mercaptopurine, 6-
anine, azathioprine, 2’-deoxycoformycin (pentostatin), erythrohydroxynonyladenine
(EHNA), fludarabine phosphate, and 2-chlorodeoxyadenosine (cladribine, 2-CdA); natural
_ 29 _
products including totic drugs such as paclitaxel, vinca alkaloids including vinblastine
(VLB), vincristine, and vinorelbine, taxotere, estramustine, and estramustine phosphate;
ppipodophylotoxins such as etoposide and teniposide; antibiotics such as actimomycin D,
daunomycin (rubidomycin), doxorubicin, ntrone, idarubicin, bleomycins, ycin
amycin), cinC, and actinomycin; enzymes such as L-asparaginase; biological
response rs such as interferon-alpha, IL-2, G-CSF and GM-CSF; miscellaneous agents
including platinium coordination complexes such as cisplatin and carboplatin, anthracenediones
such as mitoxantrone, tuted urea such as hydroxyurea, methylhydrazine derivatives
including N—methylhydrazine (MIH) and procarbazine, adrenocortical suppressants such as
mitotane (o,p’-DDD) and aminoglutethimide; hormones and antagonists including
adrenocorticosteroid antagonists such as prednisone and equivalents, dexamethasone and
aminoglutethimide; progestin such as hydroxyprogesterone caproate, medroxyprogesterone
acetate and megestrol acetate; estrogen such as diethylstilbestrol and ethinyl estradiol
equivalents; antiestrogen such as tamoxifen; androgens including testosterone propionate and
fluoxymesterone/equivalents; antiandrogens such as flutamide, gonadotropin-releasing
hormone analogs and leuprolide; and non-steroidal antiandrogens such as flutamide.
[00 1 0 7] In addition, the vActRHB polypeptides ofthe t invention are useful for
detecting and quantitating myostatin, activin A, or GDF-ll in any number of assays. In
general, the ActRIIB polypeptides of the present invention are useful as capture agents to bind
and immobilize tin, activin A, or GDF-ll in a variety of assays, r to those
described, for example, in Asai, ed., Methods in Cell Biology, 37, Antibodies in Cell Biology,
Academic Press, Inc., New York (1993). The polypeptides may be labeled in some manner or
may react with a third molecule such as an antibody which is labeled to enable myostatin to be
detected and quantitated. For example, a polypeptide or a third molecule can be modified with
a detectable moiety, such as biotin, which can then be bound by a fourth molecule, such as
enzyme-labeled streptavidin, or other proteins. (Akerstrom, J Immunol 135:25 89 (1985);
Chaubert, Mod Pathol 5 (1997)).
[00 1 0 8] The invention having been described, the following examples are d by
way of ration, and not limitation.
EXAMPLES
E 1: EXPRESSION AND PURIFICATION OF VACTRIIB POLYPEPTIDES
[00 1 0 9] The ing methods were used for expressing and purifying the variant
ActRIIB polypeptides.
[00 1 1 0] The cDNA of the human actiVin type IIB receptor was isolated from a cDNA
library of human testis origin (Clontech, Inc.) and cloned as described in US. application serial
no: 11/590,962, US. application publication No: 2007/0117130.
DETERMINATION OF AMINO ACID SUBSTITUTIONS
[00 1 1 1] The combined approaches of structure analysis, molecular modeling, and mass
spectrometry ted that aggregation (oligomerization) may arise in ActRIIB through
olecular disulfide bond formation triggered by electrostatic and H-bonding interactions
between nonglycosylated ActRIIB molecules. The residues 28 and 40 were determined to be
involved in ActRIIB:ActRIIB interactions and not in ActRIIB interactions with its ligands.
[00 1 1 2] Initially, E28 and R40 on ActRIIB-Fc were substituted with A at each position.
Light scattering and mass spectrometry analyses confirmed that the n of fully
ylated VActRIIB-IgGch, E28A, and VActRIIB-IgGch R40A was significantly
increased compared to wild-type protein. E28A and R40A VActRIIB-IgGch were ted
at 37 °C for 6 days, resulting little or no aggregation compared to wild type. Amino acid
substitutions at positions 28 and 40 (with respect to SEQ ID NOS: 2 and 18 with the signal
sequence) were made to alleviate or prevent aggregation that can occur during expression or
purification of the wild-type ActRIIB (SEQ ID NOS: 2 and 18). This ation has been
identified as structured oligomer formation during sion and non-structured aggregate
generation both during expression and after protein purification.
[00 1 1 3] Aggregation at different stages of the production and ation processes was
determined using size exclusion tography according to the ure below.
[00 1 1 4] The following exemplary method was used to produce the variant ActRIIB
polypeptides (VActRIIB and VActRIIBS). Polynucleotides encoding the VActRIIB, E28W
(SEQ ID NO: 23) were fused to polynucleotides encoding human IgG1 Fc domain (SEQ ID
NO: 82) or polynucleotides encoding human IgG2 Fc (SEQ ID NO: 84), Via a hinge linker
sequence (nucleotides encoding SEQ ID NO: 79) using PCR overlap extension using primers
containing the mutation resulting in E28W. The fill polynucleotide sequence is SEQ ID NO:
61. Double stranded DNA fragments were subcloned into pTTS (Biotechnology Research
Institute, National ch Council Canada (NRCC), 6100 Avenue Royalmount, Montreal
(Quebec) Canada H4P 2R2), pDSROL (described in WO/9014363) and/or derivatives of pDSR0L.
In other embodiments, polynucleotides encoding IB polypeptides were attached to
polynucleotides encoding linker GGGGS (SEQ ID NO: 75) or multimers thereof, and or hinge
linkers (such as SEQ ID NO: 79).
[00 1 1 5] Transient expression of engineered vActRIIB-Fc and vActRIIB5-Fc was carried
out as follows.
[00 1 1 6] The engineered variants of the above two molecules were expressed transiently
in serum-free suspension adapted 293-6E cells (National Research Council of Canada, Ottawa,
Canada) maintained in FreeStyleTM medium (Invitrogen ation, Carlsbad, CA)
supplemented with 250 ug/ml geneticin (Invitrogen) and 0.1% Pluronic F68 (Invitrogen).
Transfections were performed as 1L cultures. Briefly, the cell inoculum was grown to 1.1 X
106 cells/ml in a 4L fernbach shake flask (Corning, Inc.). The shake flask culture was
maintained on an Innova 2150 shaker platform (News Brunswick Scientific, Edison, NJ) at 65
RPM which was placed in a fied incubator maintained at 37°C and 5% CO2. At the
time of transfection, the 293-6E cells were diluted to 1.0 X 106 cells/ml.
[00 1 1 7] The transfection complexes were formed in 100 ml FreeStyle medium. 1 mg
plasmid DNA was first added to the medium ed by 3 ml of FuGene HD ection
reagent (Roche Applied Science, Indianapolis, IN). The transfection complex was ted at
room temperature for approximately 15 minutes and then added to the cells in the shake flask.
Twenty-hour hours post ection, 20% (w/v) of peptone TNl (OrganoTechnie S.A.,
TeknieScience, QC, Canada) was added to reach a final concentration of 0.5% (w/v). The
transfection/expression was performed for 4-7 days, after which the conditioned medium was
harvested by centrifilgation at 4,000 RPM for 60 minutes at 4°C.
[00 1 1 8] Stable ection and expression was carried out as follows. The vActRIIB-
human (hu) IgG2-Fc cell lines were created by transfecting stable CHO host cells with the
sion ds pDC323-vActRIIB (E28W)—hngG2 EC and pDC324-vActRIIB (E28W)-
hngG2 Fc (according to Bianchi et al., Biotech and Bioengineering, 84(4):439-444 (2003))
using a standard electroporation procedure. After transfection of the host cell line with the
sion plasmids the cells were grown in serum-free selection medium without GHT for 2-3
weeks to allow for selection of the plasmid and recovery of the cells. Cell are selected until
they achieved greater than 85% viability. This pool of transfected cells was then cultured in
medium containing 150 nM methotrexate.
CELL LINE CLONING
[00 1 1 9] A cell bank was made of selected clones according to the ing procedure.
An amplified pool of stable transfected cells was seeded in 96-well plates, and ate clones
were evaluated for growth and productivity mance in small-scale studies. Pre-master cell
banks (PMCB) of approximately 60 vials were prepared from the chosen clone. All PMCBs
were tested for sterility, mycoplasma and viruses.
[00 1 2 0] A vActRIIB-Fc expressing cell line was scaled up using a typical fed-batch
process. Cells were inoculated into a Wave bioreactor (Wave h LLC). Culture was fed
three times with bolus feeds. 10L were harvested on day 10, the remainder was harvested on
day 11; both harvests underwent depth filtration followed by sterile filtration. The conditioned
media was filtered through a 10 inch 0.45/02 micron pre filter, ed by a filtration through
a 6 inch 0.2 micron filter.
PROTEIN PURIFICATION
[00 1 2 1] Approximately 5 L of the conditioned medium ning ActRIIB-Fc (both
IgG1 and IgG2), ActRIIBS-Fc (both IgG1 and IgG2), and variants of these were concentrated
using a 5 ft2 10K ne tangential flow filter (Pall). The concentrated material was
applied to a 5 mL Protein A High Performance ColumnTM (GE care) which had been
equilibrated with PBS cco’s with no magnesium chloride or calcium chloride). After
washing the column with the equilibration buffer until the absorbance at 280 nm (OD280) was
less than 0.1, the bound protein was eluted with 0.1 M glycine-HCl, pH 2.7, and immediately
neutralized with 1 M Tris-HCl, pH 8.5. The neutralized eluted pool was concentrated to a
volume of 1 ml and applied to a 320ml Sephacryl -200 column (GE Healthcare) that was
equilibrated in PBS cco’s with no magnesium chloride or calcium chloride. A 4-20%
SDS PAGE gels (Invitrogen) were run to determine which fractions to pool. These
polypeptides were tested for activity, and degree of aggregation, as shown below.
[00 1 22] Optionally, the polypeptides can be further purified, using for example, using a
Shp-Sepharose column. Concentration was determined using OD280.
EXAMPLE 2: IN VITRO ACTIVITY ASSAYS
[00 1 23] Samples of vActRIIB polypeptides d as described above were diluted
with phosphate-buffered saline (PBS: 2.67 mM potassium chloride, 138 mM sodium chloride,
1.47 mM potassium phosphate monobasic, 8.1 mM sodium phosphate dibasic, pH 7.4) to 0.2
mg/ml, ted at 37 °C for 6 days, then applied to MALDI-MS (matrix-assisted laser
_ 33 _
desorption/ionization mass ometry), SEC and/or SEC-LS analyses. The aggregation of
the wt and variant polypeptides after the protein A purification step were determined using SEC
or SEC-LS, and the lar weight of the molecules confirmed using the MALDI-MS
procedure described below.
[00 1 24] Size exclusion chromatography (SEC). Experiments were performed on an
Agilent 1100 HPLC system with two s (TOSOHAAS G3000swxl, 7.8 X 300 mm) in
tandem. 2x PBS was used as the mobile phase at 0.5 ute.
[00 1 2 5] Size exclusion chromatography-light scattering (SEC-LS). Experiments were
performed on an Agilent 1100 HPLC system with a Superdex-200 gel ion column
(Amersham Pharmacia, Waukesha, WI). The s were then passed through a Wyatt
miniDawn LS laser light scattering detector and Wyatt Optilab DSP Refractometer (Wyatt
Technology Co., Santa Barbara, CA) to determine the molecular mass. PBS was used as the
mobile phase at 0.4 ml/minute.
[00 1 2 6] Matrix-Assisted laser Desorption /Ionization Mass Spectrometry. s were
mixed (1 : l) with sinapinic acid and applied to MALDI-MS (Applied tems Voyager
System 2009). This procedure was used to check molecular weight of the molecules.
[00 1 2 7] Determination of binding affinity, and IC50 values for activin and myostatin
were obtained as described below.
[00 1 2 8] Qualitative BIAcore® Assay. E28 and R40 were substituted respectively with
other natural amino acids in fusions with IgGl PC as bed above. These were generated
with or without linkers, as shown in the Tables below. Each vActRIIB-IgGch sample from
conditioned media was captured on goat uman IgGl Fc antibody (Jackson Immuno
Research, cat# 109098, lot 63550) coated CM5 surface. 20 nM of Activin A was ed
over captured sample surfaces using BIACore2000 (BIACore Life Sciences, Piscataway, New
). The resulting sensorgrams were normalized to the captured RL (500 RU) of
vActRIIB-IgGch variants. The normalized binding response (RU) for some variants are
shown in Table 2, and is further bed below. Relative binding y for activin was also
determined by Biacore measurements using conditioned media obtained from mammalian cell
expression. Activin A (20 nM) was used to capture soluble receptor polypeptide in the
conditioned media and measured SPR signals were normalized. Normalized SPR of +++++: >
60,++++140——60,+++:20——40,++:10——20,+:5——10,-:<5.
[00 1 2 9] Table 1A and Table 1B summarize the results of the relative binding data. The
table below shows that certain embodiments of the vActRIIB-IgGch in particular bound to
activin A with higher affinity than wild type, or retained comparable affinity with the wild type.
WO 06175
Table 1A: Wild-type and Engineered ActRHB-IgGl Fc Binding (Stable Transfectants)
Relative
. Linker (SEQ
actiVin
-cno nnnnns nonconzo
-cno s noon
-CH0 ActRIIBS E28A GGGGS
-CHO ActRIIBS E28W R4OA GGGGS
-CHO ActRIIB none (E28) GGGGS
-CHO ActRIIB E28A GGGGS
-CHO ActRIIB E28A 2(GGGGS)
cos nnnnn <n2s>
cos nnnnn noon
cos ActRIIB none (E28) R4OA
Table 1B: Wild-type and Engineered ActRHB-IgGl Fc Binding (Transient Transfectants)
Relative
. Linker (SEQ
actiVin
bindin_
cos ActRHB E28W GGGGS
cos ActRHB E28Y GGGGS
cos ActRIIB none (E28) R4OG GGGGS
cos ActRHB E28F GGGGS
cos ActRIIB none (E28) GGGGS
cos —————-—+
cos nnnnnn noon ocoos —
. Relative
L1nker (SEQ
CHO Expression Molecule Res28 Res40 activin
ID NO. 75)
bindin'
cos —————-
C2C12 CELL BASED ACTIVITY ASSAY
[00 1 3 0] vActRIIB5-IgG1Fc and vActRIIB-IgGch variants were generated as described
above. The y of these variants to inhibit the binding of activin A or myostatin to the
activin IIB receptor was tested using a cell bascd activity assay as described below.
[0 0 1 3 1] A myostatin/activin/GDF-l 1-rcsponsivc reporter cell line was ted by
transfection of C2C12 myoblast cells (ATCC No: CRL-1772) with a pMARE-luc uct.
The pMARE-luc uct is made by cloning twclvc s of thc CAGA sequence,
representing the myostatin/activin response clcmcnts (Dcnnlcr ct al. EMBO 17: 3091-3100
(1998)) into a pLuc-MCS reporter vector (Stratagcnc cat # 219087) upstream of the TATA box.
The C2C12 cells naturally express activin or IIB on their cell surface. When
myostatin/activinA/GDF-ll binds the cell ors, the Smad pathway is activated, and
phosphorylatcd Smad binds to the response element (Macias-Silva ct al. Cell 87: 1215 (1996)),
resulting in the expression of thc lucifcrasc gcnc. Lucifcrasc activity was then measured using
a commercial rasc reporter assay kit (cat # E4550, Promega, Madison, WI) according to
manufacturer’s protocol. A stable line of C2C12 cells that has been transfcctcd with pMARE-
luc (C2C12/pMARE) was used to measure activity according to the following procedure.
Reporter cells were plated into 96 well cultures. Screening using dilutions of the wild type and
variant ActRIIB-IgGl Fc fusions constructed as described above was performed with the
concentration fixed at 4 nM activin. Activin A was cubated with the receptors at several
concentrations. Activin activity was measured by determining the rase activity in the
treated cultures. The IC50 values were determined for each polypeptide. These are shown in
Table 2. The same procedure was followed for ActRIIB-hngG2 Fc fusions produced as
described above for the determination of myostatin. Protein A purified wt and variants were
used in the determination of IC50 values for myostatin using the same methodology. For this
determination, the polypeptides were pre-incubated with 4 nM myostatin. In addition, the
degree of aggregation was ined using the procedures described above. These values are
given in Table 3 below.
[00 1 3 2] Out of the set of ActRIIB5-IgG1 Fc variants that are listed in Table 1A, several
ActRIIB-IgGl Fc variants and three ActRIIB5-IgG1 Fc variants together with the wild type
polypeptides were fiarther purified and analyzed by SPR (surface plasmon resonance) at 20 nM
activin A. Table 2 shows the SPR binding affinity of selected vActRIIB-IgGl Fc polypeptides
for activin. n A (20 nM) was used to capture vActRIIB polypeptides in the samples and
ed SPR signals were normalized. IC50 values were obtained from cell-based activin
inhibition assays bed above. Standard errors are less than 10% for all results.
Table 2
. SPR normalized RU
Var1ant IC50 (nM) Act1v1n. .
(RU 2 response unit)
ActRIIB-IgGch (SEQ 35 8.20
ID NO:58)
vActRIIB-IgGch, 20 25.30
E28A (SEQ ID NO:60)
vActRIIB-IgGch, 128 2.07
E28W (SEQ ID NO:62)
vActRIIB-IgGch, 115 2.10
E28Y (SEQ ID NO:64)
vActRIIB-IgGch, 18
R40G (SEQ ID NO:66)
ActRIIB5-IgG1Fc (SEQ 37
ID NO:68)
IB5-IgG1Fc, 8
E28A (SEQ ID NO:70)
vActRIIB5-IgG1Fc, 45 16.86
E28W (SEQ ID NO:72)
2012/070571
[00 133] As shown above in Table 2 above, the ICSO value of vActRIIB-IgGch (E28W)
for blocking activin was 2.07 nM and the ICSO value of vActRIIB-IgGch (E28Y) was 2.1 nM
ed to wild type. Furthermore, the E28W and E28Y variants ofvActRHB-IgGch were
stable and not aggregated once purified.
[00 1 3 4] The ICSO value in a myostatin blocking cell based assay was determined for
additional variant polypeptides as well. These variants were the mature truncated vActRHB
polypeptides lacking the signal sequence and the first six amino acids of the N—terminal. These
sequences are shown in Table 3. Table 3 shows the percent aggregation of the protein after
protein A purification, and the ICSO value with respect to myostatin. It can be seen that the
percent aggregation is much less for the variant polypeptides ed with the wild type.
Similar results were obtained for mature truncated vActRHB polypeptides without the signal
sequence and the N—terminal four amino acids, and with identical tutions as shown below.
Table 3
IC50 (HM)
Ac\tfl:rIiI:fiFc 0
ActRIIB
a re/Oation myostatin
gg g
cell based
hActRIIB- ETREZSCIYYNANWEL GGGGS PSVFLFPP
hIngFc ERTNQSGLERCEGEQ VECPPC KPKDTLMISRTPEV
(SEQ ID DKRLHCYASWRNSS P (SEQ TCVVVDVSHEDPE
NO: 89) GTIELVKKGCWLDDF ID VQFNW Y VDGVEV
NCYDRQECVATEENP NO:79) HNAKTKPREEQFN
CEGNFCNER STFRVVSVLTVVH
FTHLPEAGGPEVTYE QDWLNGKEYKCK
PPPTAPT (SEQ ID NO: PAPEIKTIS
86) KTKGQPREPQVYT
LPPSREEMTKNQVS
LTCLVKGFYPSDIA
VEWESNGQPENNY
KTTPPMLDSDGSFF
LYSKLTVDKSRWQ
QGNVFSCSVMHEA
LHNHYTQKSLSLSP
GK (SEQ ID NO: 80)
IC50 (HM)
AcéRHBEFC 0A)
ActRIIB myostatin
arian aggrega 1011t'
cell based
hActRIIB- ETRW28CIYYNANWE GGGSV APPVAGPSVFLFPP
hIngFc LERTNQSGLRCEGEQ ECPPCP KPKDTLMISRTPEV
(E28W) DKRLHCYASWRNSS (SEQ ID TCVVVDVSHEDPE
(SEQ ID GTIELVKKGCWLDDF NO:79) VQFNWYVDGVEV
N09 1) NCYDRQECVATEENP HNAKTKPREEQFN
QVYFCCCEGNFCNER SVLTVVH
FTHLPEAGGPEVTYE QDWLNGKEYKCK
PPPTAPT (SEQ ID NO: VSNKGLPAPIEKTIS
87) KTKGQPREPQVYT
LPPSREEMTKNQVS
LTCLVKGFYPSDIA
VEWESNGQPENNY
KTTPPMLDSDGSFF
LYSKLTVDKSRWQ
QGNVFSCSVMHEA
LHNHYTQKSLSLSP
GK SEQ ID NO: 80
hActRIIB- ETRY28CIYYNANWEL GGGGS APPVAGPSVFLFPP
hIngFc ERTNQSGLERCEGEQ VECPPC KPKDTLMISRTPEV
(E28Y) DKRLHCYASWRNSS P (SEQ TCVVVDVSHEDPE
(SEQ ID GTIELVKKGCWLDDF ID VQFNWYVDGVEV
NO: 93) CYDRQECVATEENPQ NO:79) HNAKTKPREEQFN
EGNFCNERF STFRVVSVLTVVH
THLPEAGGPEVTYEP QDWLNGKEYKCK
PPTAPT (SEQ ID VSNKGLPAPIEKTIS
NO:88) KTKGQPREPQVYT
LPPSREEMTKNQVS
LTCLVKGFYPSDIA
VEWESNGQPENNY
KTTPPMLDSDGSFF
LYSKLTVDKSRWQ
QGNVFSCSVMHEA
QKSLSLSP
[00 1 3 5] Table 4 fies the sequences corresponding to SEQ ID NOS: 1-99 in the
sequence listing.
Table 4
SEQ Description
ID NO
1 BS extracellular domain, .01 tide
2 ActRIIBS ellular domain, .01 ooetide
3 VActRIIBS E28A ol nucleotide
4 VActRIIBS E28A ool ooetide
VActRIIBS E28A and R40A ool nucleotide
6 VActRIIBS E28A and R40A ool ooetide
7 VActRIIBS E28W ool nucleotide
8 VActRIIBS E28W ool ooetide
9 VActRIIBS E28Y ol nucleotide
SEQ Description
ID NO
VActRIIBS E28Y tide
11 VActRIIBS E28X wherein X is A, F, Q, V, I, L, M, K, H, W or Y
.01 nucleotide
12 VActRIIBS E28X wherein X is A, F, Q, V, I, L, M, K, H, W or Y
.01 ..etide
13 VActRIIBS E28X and R40X,
wherein X(28) is A, F, Q, V, I, L, M, K, H, W or Y
wherein X(40) is A, G, Q, M, H, K or N
.01 nucleotide
14 VActRIIBS E28X and R40X,
wherein X(28) is A, F, Q, V, I, L, M, K, H, W or Y
wherein X(40) is A, G, Q, M, H, K or N
.01 ..etide
VActRIIBS R40X wherein X is G, Q, M, H, K or N 0.1 nucleotide
16 VActRIIBS R40X wherein X is G, Q, M, H, K or N .01 .e.tide
17 ActRIIB extracellular domain, .01 nucleotide
18 ActRIIB extracellular domain, .01 .e.tide
19 VActRIIB E28A .01 nucleotide
VActRIIB E28A .01 .e.tide
21 VActRIIB E28A and R40A .01 nucleotide
22 VActRIIB E28A and R40A .01 .e.tide
23 IB E28W .01 nucleotide
24 VActRHB E28W .01 .e.tide
VActRIIB E28Y .01 nucleotide
26 VActRIIB E28Y .01 .e.tide
27 VActRIIB E28X wherein X is A, F, Q, V, I, L, M, K, H, W or Y
.01 nucleotide
28 VActRIIB E28X wherein X is A, F, Q, V, I, L, M, K, H, W or Y .01 .e.tide
29 VActRIIB E28X and R40X,
wherein X(28) is A, F, Q, V, I, L, M, K, H, Y or W
wherein X(40) is A, G, Q, M, H, K or N
.01 nucleotide
VActRIIB E28X and R40X,
wherein X(28) is A, F, Q, V, I, L, M, K, H, Y or W
wherein X(40) is A, G, Q, M, H, K or N
.01 e
31 VActRIIB R40X wherein X is G, Q, M, H, K or N .01 tide
32 VActRIIB R40X wherein X is G, Q, M, H, K or N .01 .e.tide
33 VActRIIB R64A, E28A .01 nucleotide
34 VActRIIB R64A, E28A .01 .e.tide
VActRIIB R64A, E28A and R40A .01 tide
36 IB R64A, E28A and R40A .01 .e.tide
37 VActRIIB R64A, E28W .01 nucleotide
38 VActRIIB R64A, E28W .01 e
39 VActRIIB R64A, E28Y .01 tide
40 VActRIIB R64A, E28Y .01 .e.tide
WO 06175
SEQ Description
ID NO
41 VActRIIB R64A, E28X wherein X is A, F, Q, V, I, L, M, K, H, Y or W
.01 nucleotide
42 VActRIIB R64A, E28X wherein X is A, F, Q, V, I, L, M, K, H, Y or W
.01 ..etide
43 IB R64A, E28X and R40X,
wherein X(28) is A, F, Q, V, I, L, M, K, H, W or Y
wherein X(40) is A, G, Q, M, H, K or N
.01 nucleotide
44 VActRIIB R64A, E28X and R40X,
wherein X(28) is A, F, Q, V, I, L, M, K, H, W or Y
wherein X(40) is A, G, Q, M, H, K or N
.01 ..etide
45 VActRIIB R64A, R40X wherein X is G, Q, M, H, K or N 0.1 tide
46 IB R64A, R40X wherein X is G, Q, M, H, K or N .01 .e.tide
47 Secuence Accession NP 001097 Wild t .e ActRIIB .01 .e.tide
48 Secuence Accession NM 002192 ActiVin A .01 .e.tide
49 Secuence Accession AAB86694 M ostatin .01 .e.tide
50 ce Accession 095390 GDF-11 .01 .e t.ide
51 IB5 E28X and R40X, wherein X = an amino acid .01 nucleotide
52 IB5 E28X and R40X, wherein X = an amino acid .01 .e.tide
53 VActRIIB E28X and R40X, wherein X = an amino acid .01 nucleotide
54 VActRIIB E28X and R40X, wherein X = an amino acid .01 .e t.ide
55 VActRIIB R64A, E28X and R40X, wherein X = any amino acid
.01 nucleotide
56 VActRIIB R64A, E28X and R40X, wherein X = an amino acid .01 .e.tide
57 ActRIIB-IG1Fc rnature .01 nucleotide
58 ActRIIB-I_G1Fc rnature .01 .e.tide
59 VActRIIB-I_G1Fc E28A E10A rnature .01 nucleotide
60 VActRIIB-I_G1Fc E28A E10A rnature .01 .e t.ide
61 VActRIIB-IGch E28W E10W rnature .01 nucleotide
62 VActRIIB-I_G1Fc E28W E10W e .01 .e.tide
63 VActRIIB-I_G1Fc E28Y E10Y rnature .01 tide
64 VActRIIB-I_G1Fc E28Y E10Y rnature .01 .e t.ide
65 VActRIIB-IGch R40G R22G rnature .01 nucleotide
66 VActRIIB-I_G1Fc rnature R40G R22G rnature .01 .e.tide
67 VActRIIB5-IGch rnature .01 nucleotide
68 VActRIIB5-I_G1Fc rnature .01 .e.tide
69 VActRIIB5-I_G1Fc E28A E10A rnature .01 nucleotide
70 IB5-I_G1Fc E28A E10A rnature .01 .e.tide
71 VActRIIB5-IG1Fc E28W E10W rnature .01 nucleotide E10W
72 VActRIIB5-I_G1Fc E28W E10W rnature .01 .e.tide E10W
73 Sinal secuence shown in Fiures 1 and 2
74 Alternative sinal se . uence
75 Linker
76 C0rn.lete hin_e re ions for IG1
77 C0rn.lete hine reion for I _G2
78 C0rn.lete hine reion for I _G4
SEQ Description
ID NO
79 Hine linker
80 LG2 Fc 0nl nnetide
81 LG2 Fc nucleotide deenerate
82 LG1 Fc 0nl nnetide
83 IG1 Fc 0nl nucleotide
84 LG4 Fc 0nl nnetide
85 LG4 Fc 0nl nucleotide—deenerate
86 ActRIIB mature truncated wt 0nl nentide
87 VActRIIB E4W E28W mature truncated 0nl nentide
88 IB E4Y E28Y mature truncated 0nl nentide
89 ActRIIB-LG2Fc mature ted 0nl nentide
90 ActRIIB-IG2 Fc mature ted 0ol nucleotide deenerate
91 VActRIIB-LG2Fc E4W E28W mature truncated 0nl nentide
92 VActRIIB-LG2Fc E4W E28W mature truncated 0nl nucleotide
93 IB-LG2Fc E4Y E28Y mature truncated 0nl nentide
94 VActRIIB-LG2Fc E4Y E28Y mature truncated 0nl nucleotide
95 VActRIIB-IG2 Fc E4A E28A mature truncated 0nl nentide
96 VActRIIB-IgG2 Fc (E4A) E28A mature truncated polynucleotide
deenerate
97 VActRIIB—IgG2 Fc (E4X) E28X—wherein X is A, F, Q, V, I, L, M, K, H,
W or Y mature truncated 0nl ne tnide
98 Fi_ure 1—ActRIIB-IG1 Fe
99 Fi_ure 2—ActRIIB5-IG1 Fc
EXAMPLE 3: IN VIVO ENTS USING VActRIIB
[00 1 3 6] All of the following animal studies were carried out using the mature truncated
VActRIIB-IgG2 Fc (E28W) polypeptide, (SEQ ID NO: 91), according to the procedures
described below.
ENT OF MUSCLE WASTING IN INHIBIN-OL DEFICIENT MICE
[00 1 3 7] Inhibin-(x is a naturally occurring tor of actiVin A. Mice lacking inhibin-(x
show significantly elevated n A levels in circulation and suffer from a lethal wasting
syndrome which is associated with the spontaneous ion of tumors such as ovarian,
testicular cancers and adrenal cancers (Matzuk et al., PNAS 91(19):8817-21 (1994), Cipriano et
al. Endocrinology 121(7): 2319-27(2000), Matzuk et al., Nature 02):3 13-9 (1992)). For
the ing experiments, inhibin-u knockout mice (C57BL/6J) were obtained from Charles
River Laboratories. The effects of the VActRIIB-IgG2 Fc E28W (SEQ ID NO: 91) (hereinafter
E28W, or E28W polypeptide, or soluble receptor E28W) on body weight and muscle mass was
examined in inhibin-OL knockout mice. A 14-day single-inj ection study in 8-week-old male
inhibin-01 knockout mice was performed. At 8 weeks of age, the male inhibin-01 knockout mice
had lost more than 25% of body weight compared to age-matched wild-type littermate control
mice. 5 of the knockout mice were given a single subcutaneous injection of E28W (30 mg/kg),
while 5 knockout mice were aneously administered an equal volume of PBS (vehicle) on
day 0. As a baseline control, 5 age-matched wild-type mice were administered a single
subcutaneous injection of vehicle on day 0. The mice were weighed at day 0, day 7 and day 14.
At the end of day 14, all the mice were sacrificed, and their lean carcass weights and calf
muscle mass were analyzed via necropsy. Over the l4-day study period, the average body
weight of the vehicle-treated knockout mice d by approximately 1.1 g from 22.5 g on
day 0 to 21 .4 g on day 14. In st, the average body weight of the E28W-treated knockout
mice showed a dramatic gain by 11 g from 22.1 g on day 0 to 33.1 g on day 14. Terminal
necropsy is revealed that the E28W polypeptide virtually doubled the lean carcass weight
and calf muscle mass in the inhibin-01 knockout mice, as shown below. The average lean
carcass weight of the E28W-treated knockout mice was approximately 14.9 g compared with
approximately 8.0 g for the e-treated knockout mice, and approximately 12.1 g for
vehicle-treated wild-type control mice. The average calf muscle weight (from both legs) of the
reated knockout mice was imately 426 mg compared with approximately 209
mg for the vehicle-treated knockout mice, and approximately 324 mg for vehicle-treated wild-
type control mice. These results demonstrate the effectiveness of the E28W polypeptide for the
treatment of disease states of weight loss and muscle wasting and are summarized in the Table
below.
_WTplusVehicle KO plus Vehicle KO plus E28W
Body Weight *#
28.64 ——/— 1.11 21.36 +/— 099* 33.10 ——/— 1.56
Lean Carcass (g) 12.07 ——/— 0.36 8.00 +/— 029* *#
14.90 ——/— 0.77
CalfMuscle (g) 0.324--/— 0.014 0.209 +/— 0012* 0.426 --/— 0.024*#
*2 P<0.05 vs. WT + Veh; #: P<0.05 vs. KO + Veh.
[00 1 3 8] The effects of the administration of the E28W polypeptide on the rates of
ion of ular and ovarian tumors were examined in male and female inhibin-01 KO
mice, respectively. In this study, 11 of the inhibin-01 knockout mice, including -old
males (n=5) and 9-week-old s (n=6), were treated with a single subcutaneous ion of
E28W (30 mg/kg), while another 11 of the inhibin-01 knockout mice, including age-matched
males (n=5 ) and females (n=6) received a single injection of an equal volume of PBS
WO 06175
(vehicle). In addition, 11 of the wild-type littermate control mice, including age-matched males
(n=5) and females (n=6) were administered a single injection of vehicle. Two weeks after the
treatment, the mice were sacrificed and subjected to necropsy to examine the rates of ion
of visually identifiable testicular and ovarian tumors. It was observed that 10 of the 11 e-
treated knockout mice developed identifiable tumors. Specifically, testicular and ovarian tumor
formations were found in 5 out of the 5 males and 5 out of the 6 females examined,
respectively. The sizes of these tumors were found to be 2-3 fold larger than the corresponding
normal testis or ovary in wild-type control mice. This is shown in Figure 3. Only 10% (1 out
of ll) of the E28W-treated inhibin-(x knockout mice showed visible tumor formation.
Specifically, in females, 1 out of 6 of the E28W-treated ut mice developed an
identifiable ovarian tumor, whereas 5 out of the 6 of the untreated female uts had little
or no change in the size or gross logy of the ovary compared with age-matched wild-
type ls. 5 out of 5 of the E28W-treated male knockout mice showed no visible tumors
with little or no change in the size or gross logy of the testis in comparison to the age-
matched wild-type controls. These s demonstrate that E28W administration was effective
in reducing the formation of testicular and ovarian tumors in the inhibin-(x KO mice, and also in
reducing the formation of melanomas, suggesting a clinical utility for the soluble receptor
therapy in cancer treatment.
[00 1 3 9] The effectiveness of the E28W polypeptide in treating anorexia was examined in
male inhibin-(x ut mice. In this study, food consumption in the n-(x knockout mice
(n=5) was significantly reduced compared to that of the age-matched wild-type mice (n=lO). It
was observed that the food intake of the E28W treated inhibin-(x knockout mice was
significantly increased during a 3-week period examined. The average weekly food intake in
the E28W-treated knockout mice increased to a level slightly higher than that in the age-
matched wild-type control mice, and was about 50% greater than the average weekly food
intake of the knockout mice treated with the vehicle. Thus, the data show that the E28W
treatment was highly effective in ameliorating ia in the inhibin-(x KO mice.
[00 1 4 0] The effect of the E28W treatment on al was examined in male and female
n-u KO mice, respectively. For males, 25 inhibin-u KO mice around 50 days of age were
administered the E28W polypeptide (10 mg/kg/wk, SC), while 26 age-matched inhibin-(x KO
mice received vehicle (PBS). 19 aged-matched wild-type male mice received vehicle and were
used as baseline control. The vehicle-treated knockout mice started dying on day 15 of the
study d 65 days of age). By day 34 of the experiment (around 84 days of age), 50 % of
the vehicle-treated knockout mice had died, and by day 78 (around 128 days of age), 100% of
them had died. In contrast, none of the 25 knockout mice treated with the E28W polypeptide,
or of the 19 wild-type control mice treated with e, died before day 78 of the study
(around 128 days of age). In the E28W-treated knockout mice, 1 out of 25 died on day 78 of
the study (around 128 days of age) and 24 out of 25 survived beyond day 100 (around 150 days
of age). No vehicle-treated wild type mice died during the 100-day study period. Similar
survival results were obtained in female inhibin-(x KO mice. 22 of female inhibin-(x KO mice
of approximately 50 days of age were treated with E28W (10 mg/kg/wk, SC), while 23 female
inhibin-(x KO mice of the same age were treated with PBS (vehicle). In the me, 17 of
wild type female control mice were d with vehicle. The vehicle-treated female knockout
mice began dying on day 40 of the study (around 90 days of age). By day 58 of the experiment
(around 108 days of age), 50% of the vehicle-treated female knockout mice had died, and by
day 86 of the study (about 136 days of age) 100% of them had died. In contrast, only about 5%
(1 out of 22) of the E28W-treated female knockout mice had died while about 90% (20 out of
22) survived beyond day 120 of the study (about 170 days of age). No vehicle-treated wild
type mice died during the l20-day study period. ore, the data demonstrate that the
E28W polypeptide therapy is effective in dramatically prolonging the survival of both male and
female inhibin-(x knockout mice. A schematic plot of the survival curves for both the male and
female ut mice is provided in Figure 4.
TREATMENT OF MUSCLE WASTING IN COLON-26 TUMOR G MICE
[00 1 4 1] Colon-26 tumor bearing mice is a widely used preclinical animal model for
ng cancer cachexia (Fujita et al., Int J Cancer 68(5):637-43 (1996), Kwak et al., Cancer
Research 64(22):8193-8 (2004)). The effect of E28W polypeptide on body weight change,
muscle mass and survival rate were studied in the tumor-bearing mice. Colon-26 (C-26) tumor
cells were subcutaneously implanted into 40 10-week-old, male CDF1 mice at 0.5 x 106 cells
per mouse. The tumor implantation was performed on day 0. Beginning on day 5 after tumor
implantation, twenty C-26 mice were treated weekly with a subcutaneous injection of 10 mg/kg
vActRIIB IgG2 Fc E28W (SEQ ID NO: 91), while twenty C-26 mice were treated with a
vehicle (PBS). At the same time, 10 age and weight matched normal mice were treated with a
vehicle (PBS) only. Body weight and food intake were determined 3 times per week. The
tumor-bearing mice were inspected twice daily for survival. Tumor sizes were measured using
rs (Ultra-Cal IV IP65 electronic caliper, Fred V Fowler Co. Boston MA) connected to a
PC er and values were automatically recorded to a worksheet in a Microsoft Excel data
file. As shown in Figure 5, two weeks after tumor tation, the mice bearing C-26 tumors
developed severe cacheXia and lost their body weight ically. E28W treatment
effectively mitigated the body weight loss in the tumor-bearing mice. The average body weight
of the bearing mice treated with E28W was significantly higher than that of the tumor-
bearing mice treated with vehicle (p<0.001, from day 7 to day 33 after tumor-inoculation.
Unpaired T test, Graph pad Software Inc. San Diego CA).
[00 1 42] There was no difference in tumor size between the E28W polypeptide treated
and vehicle treated groups indicating that the treatment had no effect on C-26 tumor growth.
Terminal necropsy analysis showed that the average lean carcass mass and calf muscle weight
of the E28W -treated C-26 tumor-bearing mice were significantly higher than those of the
tumor-bearing mice treated with e (p<0.001 for both lean carcass and calf ). The
effect of the E28W on survival of the C-26 tumor-bearing mice is shown in Figure 6. The
vehicle treated mice began dying at about day 14 post tumor implantation. At day 35 post
tumor implantation, all 20 vehicle treated C-26 tumor-bearing mice died; however 17 out of 20
C-26 tumor-bearing mice treated with E28W were still surviving. Thus, the E28W treatment
led to a significant prolongation of survival of the C-26 tumor-bearing mice 001, chi-
square test). Therefore, the E28W polypeptide was not only effective in maintaining body
weight and muscle mass but also in prolonging the survival of the C-26 tumor-bearing mice.
ENT OF HINDLIMB SUSPENSION MICE
[00 1 43] The mb suspension mouse model was used to examine the effect of the
vActRIIB-IgG2 Fc E28W (SEQ ID NO: 91) on muscle mass in disuse state. Hindlimb
suspension procedure is essentially the same as previously reported by Carlson CJ el al
(Carlson CJ, Booth FW and Gordon SE: Am J Physiol Regul Integr Comp l. 277: R601-
RR606, l999).Nine-week-old female C57BL/6 mice were used for the study. A total of 60
mice were divided into three groups as follows: 1. Non-suspended ne control group (20
mice) treated with vehicle (PB S), 2. Hindlimb suspension group (20 mice) treated with
vehicle, and 3. Hindlimb suspension mice group (20 mice) treated with vActRIIB-IgG2 Fc,
E28W. Specifically, a single SC injection of either 30 mg/kg of vActRIIB-IgG 2 Fc E28W or
vehicle was given to the above described groups respectively, at the time of the initiation of
hindlimb suspension. Body weight s were measured udinally 2-3 times per week.
mice from each group were sacrificed at the following 4 different time points: day 1, day 3,
day 7 and day 14. Calf muscle weights were determined via necropsy.
[00 1 44] As shown in the Table below, hindlimb suspension led to a significant loss in
body weight up to 10%. Treatment of the hindlimb suspended mice with vActRIIB-IgG2 Fe
E28W led to a significant body weight gain to a level higher than either the vehicle treated
mb suspension group or the non-suspended baseline control group as analyzed by
ANOVA measurement. During the ek study period, the e body weight gain of
the vActRIIB-IgG2 Fc E28W (SEQ ID NO: 91) treatment group was 12.6% in comparison to
the 0.2% drop in the vehicle-treated suspension group and 4.8% weight gain in the non-
suspened baseline control group, respectively. Time-course necropsy results showed that the
mb muscle mass changed in parallel to the body weights. Treatment of the suspended
mice with vActRIIB-IgG2 Fc (E28W) tely mitigated the muscle loss. Therefore, the
results of this experiment show that E28W is effective in the treatment of muscle atrophy
associated with disuse.
Group/days (body day 3 (%) day 7 (%) day 14 (%)
weight change %)
Non-HS + PBS
HS -- vehicle 400%
HS -- E28W, 30 -9.7% 2.1% 12.6%
mg/ml
TREATMENT OF OVX MICE
[00 145] Ovariectomized female C57Bl6 mice (OVX) are considered to be a model for
female hypogonadism and osteoporesis. 24 female C57Bl6 mice were ovariectomized at age
3 months and allowed to recover for 3 months. At age 6 months, 24 OVX mice as well as 24
age-matched sham operated l C57Bl6 mice were measured for longitudinal changes in
body weight, muscle, and fat mass by NMR and bone mass (PIXImus—GE LUNAR
Corporation) over a 3 month treatment period. At the end of the period, the animals were
ced, and the bone tissues harvested during terminal necropsy and subjected to Faxitron
X-ray and microCT (Faxitron X-ray Corporation and GE Medical system) analysis. It was
demonstrated to the E28W variant receptor (SEQ ID NO: 91) was effective at increasing body
, specifically lean skeletal muscle mass, and bone mass, while decreasing fat content of
the mice to the level seen in ariectomized mice. Specifically, over a 12 week period,
lean muscle mass was increased from 20 g to 27.0 g for OVX mice d with E28W,
compared with 20 g to 27.5 g for sham operated mice treated with E28W, compared with
almost no increase in lean muscle mass for OVX plus vehicle or sham plus vehicle (about 19
grams for OVX plus vehicle and about 20 g for wild type plus vehicle). In the same study,
OVX mice treated with E28W showed d fat mass from 8 g average per animal to about 4
g average per , comparable with the sham operated animals, by the end of the 12 week
study. The OVX mice treated with the vehicle, in contrast, did not lose fat mass at any time
during the study. Finally, bone mass was increased in the OVX mice treated with E28W
compared with vehicle treated OVX mice. Analysis of femur/tibia BMC (Bone mineral
t) of the dissected bone harvested during terminal necropsy was determined by pQCT
analysis (Peripheral Quantitative Computed Tomography). The OVX mice treated with E28W
sed BMC of about 0.045 g/cm to about 0.055 g/cm at the end of the 12 week study,
which is comparable to the final BMC of sham operated vehicle treated animals. The OVX
mice treated with vehicle showed about the same BMC of 0.045 g/cm at the end of the 12 week
study. The E28W d wild type mice showed an increase ofBMC from about 0.054 g/cm
to about 0.065 g/cm at the end of the 12 week study. These studies demonstrate the
effectiveness of the E28W polypeptide as potential treatments of frailty, osteoporesis, and
obesity in aging.
EXAMPLE 4: TREATMENT OF CANCER WITH SACTRIIB (E28W — SEQ ID NO. 91)
[00 1 4 6] Activin levels in mice with n cancer (OC) was investigated (Figure 7A).
Circulating activin A levels were significantly elevated in mice with ovarian cancer (OC)
compared to normal control subjects (Normal). Serum activin A was measured by ELISA.
The effect of n cancer treatment with sActRIIB (E28W) (SEQ ID. NO: 91) is shown in
Figures 7B-7D. 12-week-old female KO mice with established ovarian tumors were d for
14 days with a single injection of IB or PBS. l, age-matched female WT
mates received PBS. It can be seen in Figure 7B that the elevated circulating levels of
activin A in the KO mice was rapidly reduced to the WT control level by sActRIIB treatment.
Serum n A was measured by ELISA at day 0, 1 and 14 after treatment.
[00 1 4 7] In Figure 7C it can be seen that sActRIIB treatment rapidly reduced the n
tumor mass in the KO mice to the WT control level. The weights of ovaries (left and right) of
individual animals were analyzed by cohorts via necropsy at day 0, 1 and 14 after treatment.
Representative gross morphology images of ovaries depicting the ic regression of the
advanced ovarian tumors in KO mice in response to 14-day sActRIIB treatment. (Figure 7D)
[00 1 4 8] Several additional observation were made in KO mice treated with sActRIIB
(data not shown). Overexpression of Activin A mRNA was seen in ovarian tumors ofKO
mice. The overexpression was prevented by sActRIIB treatment. Additionally, sActRIIB
treatment completely blocked the increase in phospho-Smad2 in ovarian tumors in KO mice.
Also, the severe loss of E-cadherin in ovarian tumors of KO mice was reversed by sActRIIB
2012/070571
treatment. y, representative immunohistochemical images showed the complete
disappearance of E-cadherin immunoreactivity from ovarian sections ofKO mice and the
reappearance of strong E-cadherin staining after l4-day treatment with sActRIIB.
[00 1 4 9] Figure 8A shows that Activin A blockade can abolish the overexpression of
VEGF in ovarian tumors in n-(x KO mice. l2-week-old female KO mice with established
ovarian tumors were d for 14 days with a single injection of sActRIIB or PBS. As
controls, age-matched female WT littermates received PBS. ELISA data reveals that the serum
VEGF levels are markedly elevated in the KO mice but are reduced to the WT control levels
after sActRIIB treatment.
[0 0 1 5 0] Additionally, in data not shown, it was observed that immunohistochemical
staining images demonstrated dramatically increased VEGF and Ang-l immunoreactivities in
the ovarian tumor sections in KO mice, which were completely abolished by sActRIIB
treatment. Western blot analysis also revealed that the expressions of tumor angiogenesis-
related proteins in, Osteropontin, l and IGFBP-2 were highly induced in ovarian
tumors in KO mice but were decreased to the WT control levels after sActRIIB treatment.
[00 1 5 1] Immunohistochemical analysis shows that sActRIIB treatment leads to caspase-
3 tion in testicular tumors in the KO mice. In Figure 8B arrows point to the active
caspase-3 immunoreactivity in the sActRIIB-treated ovarian tumor section where residual
tumor cells are clustered. There was an absence of active caspase-3 immunostaining in the
PBS-treated ovarian tumor section. The histogram on the right shows the tative analysis
of active caspase-3 based on multiple ovarian sections from 3 animals in each group.
[00 1 52] In another experiment, it was shown that n A antagonism suppressed
angiopoeitin-l overexpression and prevented neovascularization in the tumor
microenvironment in TOV-21G human ovarian cancer xenografts. Implantation of TOV-21G
ovarian cancer xenografts resulted in elevated activin A in circulation in CD1 nude mice.
Activin A was measured by ELISA . Administration of activin A nist, sActRIIB
suppressedTOV-ZlG tumor growth in CD1 nude mice. The G xenografts-bearing mice
were treated with sActRIIB, or with PBS at day 12 post tumor implantation.
[00 1 53] Blocking activin A had no direct effect on the proliferation in vitro of TOV-21G
cells in cell es. Growth of TOV 21G cells was monitored “by real time in vitro micro-
imaging” using the IncuCyte system. The n A inhibitors were added at the time of cell
g. Staurosporin, as a positive control for inhibition of cell growth, was used to
demonstrate the ility of the monitoring system.
[0 0 1 5 4] Blocking activin A suppressed Ang-l overexpression and inhibited tumor
neovascularization in TOV-21G n tumor xenografts. TOV-21G afts-bearing nude
mice were treated with sActRIIB or PBS at day 12 post tumor implantation. The TOV-ZlG
tumors were isolated at different time points after the treatment and then subjected to
immunohistochemical staining for Ang-l and CD31 as a marker of neovasculature . Cell nuclei
were counterstained.
[00 1 5 5] Caspase-3 tion and cancer cell apoptosis in G xenograft tumors
also followed blocking of activin A. TOV-ZlG tumor sections were histochemically
examined for caspase-3 activation using active caspasespecif1c antibody and for cell
apoptosis using TUNEL staining. sActRIIB induced active caspase-3 and cell apoptosis.
[00 1 5 6] The experiments demonstrate that activin A is capable of stimulating
angiogenesis factor overexpression (e. g., VEGF-A and Ang-l) by multiple cell types (i.e.,
cancer, endothelial, fibroblast and tic cells), whereas blocking the elevated activin A in
tumors prevented overexpression of angiogenic factors and as a consequence activated caspase-
3 and cell apoptosis, leading to tumor ssion.
EXAMPLE 5: OVARIAN AND TESTICULAR MORPHOLOGY
[00 1 5 7] Histological examination of ovarian and testicular tumors in lO-week-old male
and l4-week-old female inhibin-(x KO mice that had been treated for two weeks with PBS or
sActRIIB along with age-matched WT controls was performed. 8-week-old male and 12-
week-old female inhibin-(x KO mice received a single injection of sActRIIB or PBS. 14 days
after the treatment, ovarian and testicular organs were collected by necropsy. Tissue sections
were subjected to Periodic Acid-Schiff Staining for ovaries and Masson’s Trichrome Staining
for testes.
[00 1 5 8] In the untreated female KO mice, the y enlarged ovaries were
predominantly filled with solid cancer mass and large hemorrhages with hardly any
recognizable les left. However, after the sActRIIB treatment, the ovaries were normal in
size, and their morphology appeared relatively normal with many recognizable follicles,
minimal cancer invasion and few hemorrhages. This microscopic analysis thus orates our
findings on tumor weight and gross morphology and confirmed that the sActRIIB treatment
caused a dramatic cancer regression in the testes and ovaries in the KO animals. In the
untreated male KO mice, the normal testicular structures were no longer recognizable by light
microscopy, as the seminiferous tubules were mostly ed by a e, undifferentiated
cancer mass. However, after the sActRIIB treatment, the testicular ures appeared
vely normal with most of the ferous tubules largely intact, although a few small
areas still contained residual cancer cells, and the number of spermatogonia cells in some
tubules was reduced.
[0 0 1 5 9] It was also noted that sActRIIB ent rapidly reduced the testicular tumor
mass in the KO mice to the WT control level. The s of testes (left and right) of
individual animals were analyzed by cohorts via sy immediately before and 14 days after
ent. For the experiment P<0.001 vs. WT l. n=6-12.
[0 0 1 6 0] Additionally, it was noted that sActRIIB abolished VEGF and Ang-l
overexpression and induced caspase-3 activation in testicular tumors in n-u KO-mice.
Angiopoietin-2 transcripts were sed toward control levels after sActRIIB treatment in
both ovarian and testicular tumors.
EXAMPLE 6: EFFECT OF THE COMBINATION OF sActRHB AND A
HERAPEUTIC
[00 1 6 1] The effect of activin antagonist sActRIIB and cytotoxic chemotherapeutic agent
-Fluorouracil on TOV-21G tumor growth inhibition in nude mice. e 9A) TOV-21G
xenografts-bearing nude mice were treated at day 12 post tumor implantation with IB, 5-
Fu, or combination of sActRIIB and 5-Fu, respectively. Changes in tumor volumes were
recorded longitudinally. It can be observed in Figure 9A that sActRIIB by itself reduces tumor
volume 34% and 5-fluorouracil (5-FU) by itself reduces tumor volume by 49%. Combining the
two together, however, decrease tumor volume by 74%.
[00 1 62] Figure 9B shows the effects of sActRIIB and dacarbazine on growth inhibition
of G361 human melanoma aft in nude mice. BALB/c nude mice were treated with
sActRIIB, dacarbazine, or sActRIIB plus dacarbazine. For dacarbazine combination study,
BALB/c nude mice implanted with G361 xenograft (5x106 cells/mouse) were treated with
sActRIIB only (10 mg/kg, SC, lX/wk), dacarbazine only (4 consecutive days of daily IP
injection at 5 mg/kg), or sActRIIB and 5-FU combination beginning at day 18 post tumor
tation. Tumor volumes were measured longitudinally by electronic caliper up to day 26
after implantation.
[00 1 63] Given that the chemotherapeutic and IB presumably act by different
mechanisms, it would not necessarily be expected that the demonstrated results, i.e. both agents
in combination would affect overall tumor growth r than either agent individually.
[00 1 64] Ovarian cancer is the deadliest of all gynecologic cancers. Activin A, a gonadal
cytokine that serves important functions in ting the menstrual cycle, is expressed strongly
in many malignancies including ovarian cancer. Neutralizing activin A eradicates ovarian
tumors established in inhibin-def1cient mice and markedly impedes the growth of multiple
activin A-secreting ovarian xenograft tumors in nude mice. Blocking activin A appears to have
no direct effect on the eration in vitro of ovarian cancer cells in cell cultures, but, in viva,
it completely abolishes the pression of angiogenesis factors (i.e., VEGF and
angiopoietins) and inhibits neovascularization in the tumor microenvironment. It, y,
induces caspase-3 activation and cancer cell apoptosis in ovarian tumors. This profound effect
in viva can be explained, at least in part, by the ability of tumor-derived activin A to trigger the
overproduction of angiogenesis s in the host’s elial cells, which reside in the tumor
microenvironment. In addition to the ovarian tumors, activin blockade was also found to inhibit
the in viva growth of at least two other cancer types (testicular tumors and melanoma) that
secrete n A. Importantly, the tumor-inhibitory effect of activin antagonism was found to
be, at least, additive to that of S-fiuorouracil or dacarbazine chemotherapy. These findings
demonstrate a function of activin A as a critical or of tumor enesis and
tumorigenesis. Blocking the elevated n A with sActRIIB, therefore, appears to be a
promising new approach to combat ovarian cancer, testicular cancer, melanoma and possibly
other malignancies.
[00 1 6 5] The present invention is not to be limited in scope by the specific embodiments
described herein, which are ed as single illustrations of individual aspects of the
invention, and filnctionally equivalent methods and ents are within the scope of the
invention. Indeed, various modifications of the invention, in addition to those shown and
described herein will become apparent to those skilled in the art from the foregoing description
and accompanying drawings. Such modifications are intended to fall within the scope of the
appended claims.
Claims (29)
1. A pharmaceutical composition comprising (i) an isolated protein comprising a variant activin IIB receptor polypeptide (vActRIIB), wherein vActRIIB comprises a ptide sequence having at least 95% identity to the amino acid sequence set forth at amino acids 25 through 134 of the sequence set forth in SEQ ID NO:18, wherein the polypeptide comprises an amino acid substitution at position 28, and wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11, and (ii) a chemotherapeutic agent.
2. The pharmaceutical ition according to claim 1, wherein the substitution at position 28 of the IB polypeptide is selected from the group consisting of A, F, Q, V, I, L, M, K, H, W and Y for E.
3. The pharmaceutical composition according to claim 1 or 2, wherein the substitution at on 28 of the vActRIIB polypeptide is selected from the group of amino acids consisting of A, W and Y for E.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the tution at position 28 of the vActRIIB polypeptide is W.
5. The ceutical composition according to any one of claims 1 to 4, wherein the chemotherapeutic agent is a side analogue, 5-fluorouracil, and/or dacarbazine.
6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the polypeptide sequence has at least 99% identity to the amino acid sequence set forth at amino acids 25 through 134 of the sequence set forth in SEQ ID NO: 18, wherein vActRIIB comprises a W amino acid substitution at position 28, wherein the isolated n further comprises an Fc domain linked to vActRIIB via a linker, wherein the sequence of the Fc domain is shown in SEQ ID NO:80, and wherein the sequence of the linker is shown in SEQ ID NO:79.
7. The pharmaceutical composition according to any one of claims 1 to 5, wherein vActRIIB comprises a polypeptide sequence having at least 97% identity to the amino acid sequence set forth at amino acids 25 through 134 of the sequence set forth in SEQ ID NO: 18.
8. The ceutical composition according to any one of claims 1 to 5, wherein vActRIIB comprises a polypeptide sequence having at least 98% identity to the amino acid sequence set forth at amino acids 25 through 134 of the ce set forth in SEQ ID NO: 18.
9. Use of an isolated protein comprising a variant activin IIB receptor ptide (vActRIIB) in the preparation of a medicament for treating cancer in a subject in combination with a chemotherapeutic agent, wherein the vActRIIB comprises a polypeptide sequence having at least 95% identity to the amino acid sequence set forth at amino acids 25 through 134 of the sequence set forth in SEQ ID NO:18, wherein the polypeptide comprises an amino acid substitution at position 28, and wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11.
10. The use according to claim 9, wherein the subject is receiving treatment with the chemotherapeutic agent.
11. Use of a chemotherapeutic agent in the preparation of a medicament for treating cancer in a subject in combination with an isolated protein comprising a t activin IIB receptor polypeptide (vActRIIB), n the vActRIIB ses a polypeptide sequence having at least 95% ty to the amino acid sequence set forth at amino acids 25 through 134 of the sequence set forth in SEQ ID NO:18, wherein the polypeptide comprises an amino acid substitution at position 28, and wherein the polypeptide is capable of binding myostatin, n A, or GDF-11.
12. The use according to claim 9, wherein the subject is receiving treatment with the isolated protein.
13. The use according to any one of claims 9 to 12, wherein treatment of the cancer comprises administering to the subject the isolated protein and the herapeutic agent
14. The use according to claim 13, n the isolated protein and the chemotherapeutic agent are administered to the subject concurrently, consecutively or sequentially.
15. Use of (i) an isolated protein comprising a variant activin IIB receptor polypeptide (vActRIIB) and (ii) a chemotherapeutic agent in the preparation of a medicament for treating cancer in a subject suffering therefrom, wherein the vActRIIB comprises a polypeptide sequence having at least 95% identity to the amino acid sequence set forth at amino acids 25 through 134 of the sequence set forth in SEQ ID NO:18, wherein the polypeptide comprises an amino acid substitution at position 28, and wherein the polypeptide is capable of g myostatin, activin A, or GDF-11.
16. The use according to any one of claims 9 to 15, wherein the substitution at position 28 of the IB polypeptide is selected from the group consisting of A, F, Q, V, I, L, M, K, H, W and Y for E.
17. The use ing to any one of claims 9 to 16, wherein the substitution at position 28 of the vActRIIB polypeptide is selected from the group of amino acids consisting of A, W and Y for E.
18. The use according to any one of claims 9 to 17, wherein the tution at position 28 of the vActRIIB ptide is W.
19. The use according to any one of claims 9 to 18, wherein vActRIIB comprises a polypeptide sequence having at least 97% identity to the amino acid sequence set forth at amino acids 25 through 134 of the ce set forth in SEQ ID NO: 18.
20. The use according to any one of claims 9 to 19, wherein vActRIIB comprises a polypeptide sequence having at least 98% identity to the amino acid sequence set forth at amino acids 25 through 134 of the sequence set forth in SEQ ID NO: 18.
21. The use according to any one of claims 9 to 20, wherein vActRIIB comprises a polypeptide sequence having at least 99% identity to the amino acid sequence set forth at amino acids 25 through 134 of the sequence set forth in SEQ ID NO: 18, wherein vActRIIB comprises a W amino acid tution at position 28, wherein the isolated protein further comprises an Fc domain linked to vActRIIB via a linker, wherein the sequence of the Fc domain is shown in SEQ ID NO:80, and wherein the sequence of the linker is shown in SEQ ID NO:79.
22. The use according to any one of claims 9 to 21, wherein the herapeutic agent is a side analogue, 5-fluorouracil, and/or dacarbazine.
23. The use according to any one of claim 9 to 22, wherein the cancer is solid tumor .
24. The use according to any one of claim 9 to 22, wherein the cancer is ovarian cancer.
25. The use according to any one of claim 9 to 22, wherein the cancer is ular cancer.
26. The use according to any one of claims 9 to 25, wherein treating the cancer comprises reducing the size of a tumor mass in the subject.
27. The use according to claim 26, wherein the tumor mass is an ovarian tumor mass or a solid tumor mass
28. The pharmaceutical composition according to any one of claims 1 to 8 as described in any example .
29. The use according to any one of claims 9 to 27 as described in any example hereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/329,897 US8501678B2 (en) | 2007-03-06 | 2011-12-19 | Variant activin receptor polypeptides and uses thereof |
US13/329,897 | 2011-12-19 | ||
PCT/US2012/070571 WO2013106175A1 (en) | 2011-12-19 | 2012-12-19 | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ626580A NZ626580A (en) | 2016-07-29 |
NZ626580B2 true NZ626580B2 (en) | 2016-11-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017248486B2 (en) | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof | |
US10407487B2 (en) | Variant activin receptor | |
US8999917B2 (en) | Variant activin receptor polypeptides and uses thereof | |
EP3101029B1 (en) | Variants of activin iib receptor polypeptides and uses thereof | |
NZ626580B2 (en) | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof | |
AU2016210719A1 (en) | Variants of activin IIB receptor polypeptides and uses thereof |